6XEVWDQFHFRGH1$ &/$66,&06
06B

&21),'(17,$/
,1)250$7,21

&OLQLFDO6WXG\3URWRFRO
7LWOH3DJH

&OLQLFDO6WXG\3URWRFRO7LWOH (YDOXDWLQJ WKH /RQJ 7HUP 2XWFRPHV DQG
'XUDELOLW\ RI (IIHFW )ROORZLQJ 7UHDWPHQW ZLWK&ODGULELQH 7DEOHWV IRU 0XOWLSOH 6FOHURVLV $Q
([SORUDWRU\ 3KDVH ,9 $PELVSHFWLYH 6WXG\ RI
3DWLHQWV
:KR3UHYLRXVO\ 3DUWLFLSDWHG LQ WKH
&/$5,7<&/$5,7< (;7 DQG 25$&/( 06
&OLQLFDO7ULDOV
6WXG\1XPEHU  06B 
$PHQGPHQW1XPEHU  
0HUFN&RPSRXQG1XPEHU  1$
6KRUW7LWOH  &/$66,& 06
6WHHULQJ&RPPLWWHH0HPEHUV  










[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
6XEVWDQFHFRGH1$ &/$66,&06
06B

&21),'(17,$/
,1)250$7,21



   




 











   





6SRQVRU 1DPH DQG /HJDO 5HJLVWHUHG
$GGUHVV )RUDOOFRXQWULHVH[FHSWWKH86 DQG&DQDGD
0HUFN.*D$ 
)UDQNIXUWHU6WU 
'DUPVWDGW*HUPDQ\ 
,QWKH86 DQG&DQDGD
(0'6HURQR5HVHDUFK	'HYHORSPHQW,QVWLWXWH
,QF
$QDIILOLDWHRI0HUFN.*D$'DUPVWDGW*HUPDQ\[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
6XEVWDQFHFRGH1$ &/$66,&06
06B

&21),'(17,$/
,1)250$7,21
$0LGGOHVH[7XUQSLNH
%LOOHULFD0$86$ 
0HGLFDO5HVSRQVLEOH 



$GGUHVV $UHV7UDGLQJ6$$QDIILOLDWHRI
0HUFN6HURQR6$_5RXWHGH&UDVVLHU
%kWLPHQW$_(\VLQV_6ZLW]HUODQG 
3KRQH 
)D[1RW$SSOLFDEOH 
HPDLO

5HJXODWRU\ $JHQF\ ,GHQWLI\LQJ
1XPEHUV (XGUD&7QXPEHU 
3URWRFRO9HUVLRQ  -XO\9HUVLRQ
5HSODFHV9HUVLRQ  -DQXDU\9HUVLRQ 
$SSURYDO'DWH  -XO\
0HGLFDO 0RQLWRU 1DPH DQG &RQWDFW
,QIRUPDWLRQ     

 (0' 6HURQR
5HVHDUFK	'HYHORSPHQW,QVWLWXWH ,QF
$UHV7UDGLQJ6$ $QDIILOLDWHRI0HUFN6HURQR
6$_5RXWHGH&UDVVLHU%kWLPHQW$_
(\VLQV_6ZLW]HUODQG 3KRQH 
(PDLO



&RQILGHQWLDOÂ±
7KLVGRFXPHQWLVWKHSURSHUW\RI 0HUFN.*D$'DUPVWDGW*HUPDQ\ RURQHRILWVVXEVLGLDULHV,WLVLQWHQGHGIRU
UHVWULFWHGXVHRQO\DQGPD\QRWÂ±LQIXOORUSDUWÂ±EHSDVVHGR QUHSURGXFHGSXEOLVKHGRUXVHGZLWKRXWH[SUHVV
SHUPLVVLRQRI0HUFN.*D$'DUPVWDGW*HUPDQ\RULWVVXEVLGLDU\ &RS\ULJKWÂ‹E\0HUFN.*D$'DUPVWDGW
*HUPDQ\RULWVVXEVLGLDU\$OOULJKWVUHVHUYHG

[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  4/84 
  Table of Contents  
Title Page  1 
Table of Contents  4 
Table of Tables  7 
Table of Figures  7 
Documentation of Protocol Amendments  ................................ ................................ ............ 9 
1 Protocol Summary  ................................ ................................ .............. 12 
1.1 Synopsis  ................................ ................................ .............................. 12 
1.2 Schema  ................................ ................................ ................................ 17 
1.3 Schedule of Activities  ................................ ................................ ......... 18 
2 Introduction  ................................ ................................ ......................... 23 
2.1 Study Rationale  ................................ ................................ ................... 23 
2.2 Background  ................................ ................................ ......................... 23 
2.3 Benefit/Risk Assessment  ................................ ................................ ....26 
3 Objectives and Endpoints  ................................ ................................ ...27 
4 Study Design  ................................ ................................ ....................... 32 
4.1 Overall Design  ................................ ................................ .................... 32 
4.2 Scientific Rationale for Study Design  ................................ ................ 35 
4.3 Justification for Dose  ................................ ................................ .......... 36 
4.4 End of Study Definition  ................................ ................................ ......36 
5 Study Population  ................................ ................................ ................. 36 
5.1 Inclusion Criteria  ................................ ................................ ................ 37 
5.2 Exclusion Criteria  ................................ ................................ ............... 37 
5.3 Lifestyle Considerations  ................................ ................................ .....37 
5.3.1  Meals and Dietary Restrictions  ................................ ........................... 37 
5.3.2  Caffeine, Alcohol, Tobacco, and Cannabinoid -containing 
Products  ................................ ................................ .............................. 38 
5.3.3  Activity  ................................ ................................ ............................... 38 
5.4 Screen Failures  ................................ ................................ .................... 38 
6 Study Interv ention(s)  ................................ ................................ .......... 38 
6.1 Study Intervention(s) Administration  ................................ ................. 38 
6.1.1  Medical Device(s) Use  ................................ ................................ .......38 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  5/84 
  6.2 Study Intervention(s) Preparation, Handling, Storage, and 
Accountability  ................................ ................................ ..................... 38 
6.3 Measures to Minimize Bias: Study Intervention Assignment and 
Blinding  ................................ ................................ .............................. [ADDRESS_603143]  ................................ ........ 41 
7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  ................................ ............................... 42 
7.1 Discontinuation of Study Intervention ................................ ................ 42 
7.1.1  Temporary Discontinuation  ................................ ................................ 42 
7.1.2  Rechallenge  ................................ ................................ ......................... 42 
7.2 Participant Discontinuation/Withdrawal from the Study  ................... [ADDRESS_603144] to Follow -Up................................ ................................ ............... 43 
8 Study Assessments and Procedures  ................................ .................... 43 
8.1 Efficacy Assessments and Procedures  ................................ ................ 44 
8.1.1  Clinical Endpoints  ................................ ................................ .............. 44 
8.1.2  Other Assessments  ................................ ................................ .............. 49 
8.2 Safety Assessments and Procedures  ................................ ................... 50 
8.2.1  Physical Examinations  ................................ ................................ ........ 50 
8.2.2  Vital Signs  ................................ ................................ .......................... 50 
8.2.3  Electrocar diograms  ................................ ................................ ............. 51 
8.2.4  Clinical Safety Laboratory Assessments  ................................ ............ 51 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  6/84 
  8.2.5  Suicidal Risk Monitoring  ................................ ................................ ....51 
8.3 Adverse Events and Serious Adverse Events  ................................ .....51 
8.3.1  Time Period and Frequency for Collecting Adverse Event and 
Serious Adverse Event Information  ................................ .................... 51 
8.3.2  Method of Detecting Adverse Events and Serious Adverse Events  ...52 
8.3.3  Follow -up of Adverse Events and Serious Adverse Events  ............... 52 
8.3.4  Regulatory Reporting Requirements for Serious Adverse Even ts .....52 
8.3.5  Pregnancy  ................................ ................................ ........................... 53 
8.4 Treatment of Overdose  ................................ ................................ .......53 
8.5 Pharmacokinetics  ................................ ................................ ................ 53 
8.6 Pharmacodynamics  ................................ ................................ ............. 53 
8.7 Pharmacogenetics  ................................ ................................ ............... 54 
8.8 Biomarkers  ................................ ................................ .......................... 54 
8.9 Immunogenicity Assessments  ................................ ........................... 54 
8.10  Health Economics  ................................ ................................ .............. 54 
9 Statistical Considerations  ................................ ................................ ....54 
9.1 Statistical Hypotheses  ................................ ................................ ......... 55 
9.2 Sample Size Determination  ................................ ................................ 55 
9.3 Populations for Analyses  ................................ ................................ ....55 
9.4 Statistical Analyses  ................................ ................................ ............. 57 
9.4.1  Handling of Missing Data  ................................ ................................ ...58 
9.4.2 Sequence of Analyses  ................................ ................................ ......... 59 
10 References  ................................ ................................ ........................... 60 
11 Appendices  ................................ ................................ ......................... 63 
Appendix 1  Abbreviations  ................................ ................................ ...................... 63 
Appendix 2  Study Governance  ................................ ................................ ............... 66 
Appe ndix 3  Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................ 72 
Appendix 4  Pharmacogenetics  ................................ ................................ ............... 76 
Appendix 5  Expanded Disability Status Scale (EDSS)  ................................ .......... 77 
Appendix 6  2017 Mc Donald Criteria (From Thompson, 2018)  ............................ 80 
Appendix 7  Sponsor Signature [CONTACT_3490]  ................................ ................................ ......83 
Appendix 8  Principal Investigator [INVESTIGATOR_24026]  ................................ ................. 84 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  7/84 
   
Table of Tables  
Table 1  Schedule of Activities: Assess ments Captured at Each Study Visit ...19 
Table 2  The 2017 McDonald criteria for diagnosis of Multiple Sclerosis in 
patients with an att ack at onset  ................................ ........................... 47 
 
Table of Figures  
Figure 1  Study Scheme  ................................ ................................ ..................... 17 
Figure 2  Data collection time windows according to relapse status at 
recruitment and for remote visits  ................................ ........................ 18 
  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  8/84 
  Protocol History  
 
Version Number  Type  Version Date  
1.0 Original Protocol  28 Jan 2019  
2.0 Amended Protocol  03 July  2020  
 
Protocol Version 2.0 ( 03-JUL -2020 ) 
This amendment is nonsubstantial based on the criteria in Article 10(a) of Directive 2001/20/EC 
of the European Parliament and the Council of the European Union because it neither significantly 
impacts the safety or physical/mental integrity of participants nor the scientific value of the study.  
 
Overall Rationale for the Amendment  
The changes implemented i n the protocol have been undertaken in order to improve the quality 
and analytic plans for data collection, by [CONTACT_470695], the time windows for data 
collection, and the definitions of study subgroups.  
  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  9/84 
  Documentation of Protocol Amendments  
 
Section #  and name   [CONTACT_470750] s Change  in the  study physician . Study physician has changed since the first 
protocol was written . 
Section 1.1 , Synopsis ;  
Section 3 , Objectives 
and Endpoints ;  
Section 4.2, Scientific 
Rationale and Design ; 
Section  9.4, Statistical 
Analysis  
 Updated definition of primary endpoint.  New definition to clarify and  
minimize ambiguity ( per Steering  Committee 
recommendation).  
Section 1.1 , Synopsis ;  
Section 3 , Objectives 
and Endpoints ;  
Section 9.4 , Statistical 
Analysis  
 Updated definition of secondary 
endpoint.  New definition to clarify and  
minimize ambiguity ( per Steering  Committee 
recommendation) . 
Section 1.1 , Synopsis ;  
Section 3 , Objectives 
and Endpoints ;  
Section [IP_ADDRESS] , 
Cognition Endpoints   BVMT -R/SDMT: clarification was 
added for these assessments to be 
collected from ORACLE MS subjects 
only in countries where these 
instruments were approv ed for the use  
in the CLASSIC MS study  These instruments were only collected in 
countries where they had been previously 
used  as part of data collection in the parent 
study; expansion to all participants would 
require additional ethical approval.  
Section 1.1 , Synopsis ; 
Section 1.3 , Schedule 
of Activities ;  
Section 3 , Objectives 
and Endpoints ;  
Section 4.1 , Overall 
Design ;    
Section 4.2 , Scientific 
Rationale and Design  Time window for collecting MRI and 
pharmacogenetic samples to be 
expanded to up to 3 months and up to 
6 months, respectively.  Window extended to accommodate patient 
requests to provide samples/complete MRI at 
a later date than planned in first protocol, as 
long as occurring within expected study 
timeframe.  
Section 1.1 , Synopsis ; 
Section 1.2 , Schema ;  
Section 1.3 , Schedule 
of Activities ;  
Section 4.1 , Overall 
Design   
 Updated description of data collection 
windows and included an additional  
study schema (Figure 2) to reflect 
details of the updated time windows for 
3 scenarios: patients without relapse  at 
screening, patients with relapse at 
screening, and patients completing a 
remote visit.  Additionally , new text 
was added to specify that it is possible 
to complete all assessments in a 
single day, and that patients 
undergoing relapse or suspected 
relapse could postpone Visit  1 (4 
weeks to 3 months from baseline) as a 
stabilization period.  Clarify the different time windows that are 
applicable according to relapse status at 
baseline and  speci fy the aim to collect the 
telephone EDSS within a comparable 
timeframe as the in -clinic EDSS among 
patients without relapse. Additionally, 
specification on potential to collect data in a 
single day was added to clarify acceptable 
practice for study sites.   The change in time 
window between screening and visit 1 has 
been expanded to allow additional time for 
stabilization before Study Visit 1 in case of 
suspected relapses.  
Section 1.1 , Synopsis ;  
Section 3 , Objectives 
and Endpoints ; 
Section [ADDRESS_603145] 
protocol.   
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  10/84 
  Section #  and name   [CONTACT_9353] 1.[ADDRESS_603146] protocol.  
 
Section 1.3 , Schedule 
of Activities ; 
Section 4.1 , Overall 
Design ;   
Section [IP_ADDRESS] , 
Expanded Disability 
Status Scale (EDSS)  Clarify that in -person Expanded 
Disability Status Scale (EDSS) to be 
collected from patients coming to clinic 
for Study Visit 1, and telephone EDSS 
to be collected for patients 
participating remotely; both modes not 
required.  Reducing burden on patients and possible 
deviations from sites not doing both the 
assessments.  
Section 1.[ADDRESS_603147] clinical visit (the later of Study 
Visit 1  or Study Visit 2 ). 
 Clarification of when this form is to be 
completed, particularly for the expanded data 
collection windows.  
Section [ADDRESS_603148] the updated status of drugâ€™s 
approval.  
Section 4.[ADDRESS_603149] protocol.  
Section 5.2 , Exclusion 
criteria ;  
Section 5.4 , Screen 
Failures  Adjustment to study time windows in 
the situation of confirmed or suspected 
relapse.  Expanded data collection window to allow 
patient to stabilize and participate .  
Section [IP_ADDRESS] , MRI 
Sub-study  Specification that the MRI could be 
postponed among partic ipants, but not 
beyond the time windows specified for 
the overall study.  Ensure there is no misunderstanding the MRI 
could be collected after the end of study (i.e. 
no later than [ADDRESS_603150] patient 
enrolled).  
Section [IP_ADDRESS] , MRI 
Sub-study  The definition of concomitant 
Cladribine (as an exclusion criterion for 
the MRI sub -study) was updated to 
reflect the availability of Cladribine by 
[CONTACT_50246], and to accommodate the 
shelf -life of Cladribine if received 
(through trial participation or 
presc ription).  The timeline for concomitant Cladribine use 
was updated in relation to shelf -life and 
commercial availability (changed since the 
time of protocol version 1).  
Section 8.3.5 , 
Pregnancy  Clarify writing of section on 
pregnancies: information to be 
collected on prospective pregnancies, 
but only expedited reporting for MRI 
sub-study participants.  Guidance on requirements for collecting and 
reporting pregnancy data in full study versus 
MRI sub -study was not entirely clear in first 
version of protocol.  
Section 9.3 , 
Populations for Analysis  Definition of  the subgroups for analysis 
updated:  
1) Subgroup Treatment Course 
in Cohort B.  
2) Subset Long -term responder  
3) Prior use of DMD   
 
1) Added details to the definition of 
subgroups according to treatment to 
clarify all subcategories are mutually 
exclusive and minimize ambiguity.  
2) Clarification on addition details of 
long-term responders will minimize 
ambiguity  
3) Prior use of DMD concern only 
CLARITY patients (Cohort B).  
 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  11/84 
  Section #  and name   [CONTACT_9353] 9.4.2 ; 
Sequence of Analysis  Updated planned number of patients to 
be included in the planned Interim 
Analysis. Specified that 
pharmacogenetics and MRI would not 
be included in the interim analysis.  Planned final number of patients  is unknown 
(enrolment  is slow due to COVID -19 
pandemic) and % canâ€™t be determined. [ADDRESS_603151] the SAP.  
Appendix 2 , Study 
Governance  Additio nal text on date of study start 
and patient recruitment.  Updated as per [COMPANY_006] Template 14 (reflecting 
requirements of the TransCelerate and new 
EU-CTR updates).  
Appendix [ADDRESS_603152] 
protocol.  
Appendix 3 , Adverse 
Events: Definitions and 
Procedures for 
Recording, Evaluating, 
Follow -up, and 
Reporting  Remove d specification of expedited 
reporting of non -serious adverse 
events of special interest .  It is not a requirement to report non -serious 
adverse events within 24 hours.  
Appendix 3 , Adverse 
Events: Definitions and 
Procedures for 
Recording, Evaluating, 
Follow -up, and 
Reporting  Specification that a positive test for 
COVID -[ADDRESS_603153] protocol  
Appendix 3 , Adverse 
Events: Definitions and 
Procedures for 
Recording, Evaluating, 
Follow -up, and 
Reporting  Clarification on w hich form ADR data 
is to be captured on, according to 
timing of awareness of the event.  Reiterate guidance given to the sites to ensure 
correct data entry.  
Throughout  Minor editorial and document 
formatting revisions.  Minor; therefore, have not been summ arized.  
  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  14/84 
  Exploratory Objectives  Endpoints (Outcome Measures)  
â€¢ Proportion of study participants diagnosed as 
Secondary Progressive MS (SPMS) without relapses 
in the 3  months prior to SPMS diagnosis  
â€¢ Proportion of study participants diagnosed as SPMS 
with relapses in the 3  months prior to SPMS 
diagnosis  
â€¢ Proportion of study participants diagnosed as 
Primary Progressive MS (PPMS) (For ORACLE MS 
study participants only)  
To assess impact on  quality of life and cognitive  
outcomes after treatment with IMP  during the period 
from the last clinical visit in the CLARITY/CLARITY -
EXT/ORACLE MS clinical trials to Study  Visit  1 in 
study participants previously treated with IMP as part 
of the Phase  III ORAC LE MS and 
CLARITY/CLARITY -EXT clinical trials.  Tertiary endpoints to be evaluated at Study  Visit  1: 
â€¢ Change in EuroQoL -5 Dimension Questionnaire (3 
level version) ( EQ-5D-3L) 
â€¢ Change in cognition as measured by [CONTACT_351987] (to be collected for ORACLE MS 
subjects  only in countries where these instruments 
were used  in the CLASSIC  MS study):   
o The Brief Visuospatial Memory Test â€“ Revised 
(BVMT -R) 
o Symbol Digit Modality  Test (SDMT)  
To assess durability of  outcome on brain imaging after 
treatment with IMP  from Baseline (i.e. the last MRI 
before first doseb of IMP;  if feasible, by [CONTACT_68089]) to within 
3 months  after Study Visit  1 in study participants 
previously treated with IMP as part of the Phase  III 
ORACLE MS and CLARITY/CLARITY -EXT clinical 
trials.  ORACLE MS, CLARITY and CLARITY -EXT study 
participants from selected sites will be invited to 
participate in a follow -up study visit (Study Visit  2) to 
take place within  3 months  (maximum [ADDRESS_603154] patient enrolled)  following 
Study  Visit  1, for evaluation of the following:   
Change in MRI assessment from Baseline (i.e. the last 
MRI before first doseb of IMP) to Study V isit 2 in:  
â€¢ Total volume of T2 lesions  
â€¢ Total number of T2 lesions  
â€¢ Number of hypointense lesions on T1 -spin echo MRI  
â€¢ Volume of hypointense lesions on T1 -spin echo MRI  
â€¢ Brain volume or surrogate (in cases where brain 
volume is not possible to assess for technical reasons, 
then 3rd ventricle diameter may be evaluated)  
â€¢ Ventricular volume  
To determine whether the high -disease activity (HDA) 
patients from the CLARITY/CLARITY -EXT clinical 
trials are more likely to be the long -term responders.  Comparison of t he responder rate in HDA patientse 
versus the responder rate in non -HDA patients from the 
CLARITY/CLARITY -EXT population.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  15/84 
  Exploratory Objectives  Endpoints (Outcome Measures)  
To evaluate differences in genetics between long -term 
responders and study participants requiring alternate 
therapi[INVESTIGATOR_470660]/CLARITY -EXT and ORACLE MS 
populations.  Correlation of genetic variations with long -term 
responders ( defined as study participants who did not 
demonstrate any evidence of disease reactivation based 
on Investigator assessment of  clinical and imaging 
outcomes until Year [ADDRESS_603155] doseb 
of IMP ) compared to other study participants who 
started on alternat e therapy less than [ADDRESS_603156] doseb of IMP for the CLARITY/CLARITY -
EXT and ORACLE MS populations.  
ARR =Annualized Relapse Rate , BVMT -R=Brief Visuospatial Memory Test Revised , CDMS =Clinically Definite Multiple 
Sclerosis , EDSS =Expanded Disability Status Scale , EQ-5D=EuroQoL -5 Dimension , HDA =High-disease activity , 
IMP=Investigational Medicinal Product , MRI=Magnetic Resonance Imaging , MS=Multiple Sclerosis , PPMS =Primary 
Progressive MS , RRMS =Relapsing -Remitting Multiple Sclerosis , SDMT =Symbol Digit Modalities Test , 
SPMS =Secondary Progressive Multiple Sclerosis.   
a Specific clinical and demographic characteristics may include gender, age, race, ethnicity, education, disease 
duration, years previous disease modifying treatment (before start of CLARITY/CLARITY -EXT/ORACLE MS) and 
disease classification (RRMS or SPMS) . 
b One dose is equivalent to one tablet.  One course of IMP is defined as 1 year of treatment with IMP (2 treatment cycles  
[weeks]) . A treatment cycle is defined as daily administration of IMP given consecutively over 4 -5 days during a 28 -day 
period. One treatment week is equivalent to 1 treatment cycle.  
c Total volume of T2 lesions; Total number of T2 lesions; Number of hypointense lesions on T1 -spin echo MRI; Volume 
of hypointense lesions on T1 -spin echo MRI; Brain volume or surrogate; Ventricular volume.  
d Mobility endpoints may be determined via EDSS scores (if available) or corresponding clinical descriptions in medical 
records . 
e 1. Patients with â‰¥2 relapses during the year prior to parent study entry, regardless of prior disease modifying drugs 
(DMD) use; 2. Patients with â‰¥1 relapse in the previous year and â‰¥1 T1 Gd+ lesions or â‰¥9 T2 lesions, while on therapy 
with other DMDs.  
Overall Design: This Phase  IV, low-interventional,  multi center , ambispe ctive study will include  
study participants treated with Cladribine Tablets or placebo  in the previously  conducted  parent 
studies . Long -term retrospective data will be collected through evaluation of medical 
charts/records  (e.g., sociodemographic and clinical characteristics, med ical and disease history, 
Secondary Progressive Multiple Sclerosis [SPMS ] conversion, Expanded Disability Status Scale 
[EDSS], details of subsequent Disease Modifying Drugs  (DMDs) , including physician questions 
on treatment decisions , date of first use of an ambulatory device or wheelchair  and relapse  history  
from end of parent study to Study Visit 1  as well as , for ORACLE MS patients only, Clinically 
Definite MS conversion [CDMS]  and Primary  Progressive MS [PPMS] diagnosis ).  
Additional prospective data will be collected at Study  Visit  1 (e.g., physical assessment, EDSS, 
Patient -Reported Outcomes  [PRO ], cognitive assessments). An optional blood sample for 
pharmacogenetic testing will be taken from patients who consent to the optional test ing. A sub -
study at Study Visit  2 involves a magnetic resonance imaging  (MRI) scan without gadolinium in 
approximately 150 patients who are willing to participate in this MRI sub -study . 
Number of Participants: No formal sample size calculation has been per formed for this 
exploratory study as enro lment is limited to eligible study participants from the parent studies . 
Therefore, as many study participants as feasibly possible will be enrolled  from this group. 
Additional considerations on the sample size of t he study are included in Section  9.2. 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  16/84 
  Study Intervention Groups and Duration: No investigational medicinal product ( IMP) will be 
administered as part of this study. The duration of the study for most patients is no more than 2 
weeks from the time of the Screening  Visit to Study Visit  1, except in the case of relapse at 
screening in which case the duration between Screening and Study Visit 1 is between 1 and 3 
months. An optional blood sample will be collected at Study Visit 1from patients who consent to 
the optional pharmacogenetic testing.  Pharmacogenetic testing  may also occur  during a subsequent 
clinical visit up to 6 months after the Screening Visit  (unless last pa tient enrolled has occurred, in 
which case the testing must occur at Study Visit 1) . For patients selected to participate in the MRI 
sub-study , an additional visit will be required  (Study Visit 2)  that will occur within a maximum of 
3 months  of Study Visit  1 (maximum [ADDRESS_603157] patient enrol ment has 
occurred ), and these patientsâ€™ total study duration will be no more than 6 months . Sites will be 
asked to enter any retrospective data into the electronic case report form  (eCRF) for this study 
within 12  weeks of enrolling  the patient.  Patients  who are eligible will be given the option of 
completing screening, Study Visit  1 and 2 (wher e facilities for MRI are available) on the same day 
if prefer to do so  and meet the eligibility  criteria on that day (e.g. abstention from alcohol or 
cannabinoid products in the preceding  24 hours) . Patients  who are undergoing relapse or suspected 
relapse at the time of screening will be invited for Study Visit  1 after a stabilization period 
determined through consultation with the medical monitor.  
Involvement of Special Committee(s):  Yes. 
  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  17/[ADDRESS_603158] relapse status at the time of screening, and for 
participants completing the study remotely.  A detailed Schedule of Activities (SoA)  is provided 
in Section  1.3. 
Figure 1 Study Scheme  
 

Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  18/84 
  Figure 2 Data collection time windows according to relapse status at recruitment 
and for remote visits  
 
 
1.3 Schedule of Activities  
Table 1 Schedule of Activities: Assessments Captured at Each Study Visit   provides 
details on the SoA.

Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 
 C O N F I D E N T I A L  
I N F O R M A T I O N  22/84 
  Form , IRB=Institutional Review Board , MS=Multiple Sclerosis , MRI=Magnetic Resonance Imaging , PPMS =Primary Progressive Multiple Sclerosis , SDMT =Symbol 
Digit Modalities Test , SPMS =Secondary Progressive Multiple Sclerosis.  
a Scheduling of  Study Visit [ADDRESS_603159] has been recruited  
b The in -person EDSS is a standardized physical neurological examination conducted in -person, including assessment of walking distance, whereas the telephone 
EDSS is a va lidated tool for telephone administration of the EDSS  
c The Study Termination  form will be completed  at the date of MRI visit  (Study Visit 2) , or Study  Visit [ADDRESS_603160] assessment  for that patient.  
 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  23/84 
  2 Introduction  
Despi[INVESTIGATOR_470661], the treatment burden of  Multiple 
Sclerosis (MS)  remains significant. The evidence of potential beneficial  effects of new 
therapi[INVESTIGATOR_470662] a short -term nature with little follow -up of original 
clinical trial participants  (Tramacere, 2015) . 
Treatment with Cladribine Tablets in [ADDRESS_603161] clinically and statistically significant benefits in patients across the spectrum of 
Relapsing -Remitting M ultiple Sclerosis  (RRMS ), across early to late stage  studie s as well as 
in treatment -naÃ¯ve or treatment -experienced patient s (Giovannoni, 2010; Leist, 2014 ; 
Section  2.2).  
Cladribine (2 -chloro -2'-deoxyadenosine [2 -CdA]) is a synthetic anti -neoplastic drug that 
belongs to the subgroup of agents called purine analog s. MavencladÂ® is approved ( European 
Medical Agency [ EMA ] approval on 25th Aug 2017 , and [LOCATION_002] ( US) Food and Drug 
Agency [FDA ] on 29th March 2019 ) for the treatment of adult patient s with highly active 
RRMS , as defined by [CONTACT_470696] , in:  
â€¢ patient s with [ADDRESS_603162] 1 T1 Gd+ lesion o r 9 or more 
T2 lesions, while on therapy with other disease modifying drugs (DMDs),  
â€¢ patient s with [ADDRESS_603163] Characteristics (SmPC ) and/or  the country specific 
label.  
2.[ADDRESS_603164], and real -
world treatment patterns in patients previously participating in the Phase  III ORACLE MS  
and CLARITY/CLARITY -EXT clinical trials  (i.e. parent studies) . The results from this study 
may be of benefit to patients  with MS  and clinicians by [CONTACT_4205][INVESTIGATOR_470663] -making.  For Scientific Rationale for Study Design see 
Section 4.2. 
2.2 Background  
Epi[INVESTIGATOR_470664] a chronic, inflammatory, demyelinating disease of the central nervous system  (CNS)  
and is the most common cause of serious neurological disability in young adults (Przybek, 
2015). With no definite cause established, MS has been hypothesi zed to result from a complex 
interaction between individual genetic susceptibility and environmental factors that act as 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  24/84 
  triggers of a self -sustained auto -immune response (Noseworthy, 2000). With a peak of onset 
averaging at the age of 30 years in both genders, MS occurs predominantly in women with a 
female:male ratio of 3:1 (Kingwell, 2013).  
Globally, th e median estimated prevalence of MS is [ADDRESS_603165] prevalence (140 and 108 patients per 100,000 population, 
respectively) (Multiple Sclerosis International Federation, 2013). Within Europe, the 
prevalence is highest in Denmark (227 patients  with MS  per 100,000 population), and Sweden 
(189 patients  with MS  per 100,000 population), while in most of the other countrie s the 
prevalence is under 100 patients  with MS  per 100,000 population (Multiple Sclerosis 
International Federation, 2013).  
Regarding incidence, globally, the median estimated incidence of MS is 2.5 per 100,000 
person -years (PY) (Dua, 2008). Regionally, the  median estimated incidence is greatest in 
Europe (3.8 per 100,000 PY) (Dua, 2008). The highest prevalence in Europe is [ADDRESS_603166] is 22 per 100,000 people in Albania (Multiple Sclerosis 
International Federation, 2013) . In the [LOCATION_002], the incidence is estimated to be 3.2 per 
100,000 PY (Multiple Sclerosis International Federation, 2013). Based on a recent study by 
[CONTACT_470697], an estimated 947,[ADDRESS_603167] MS 
(Wallin , 2017 ). 
Studies indicate that patients  with MS  show a nearly 3 -fold increase in mortality relative to 
the general population, and about half of them are attributed to MS as the underlying cause of 
death (Scalfari, 2013).  
Clinical Presentation and Categoriza tion of MS  
MS is not characterized  by a singular, well -defined clinical presentation common to all 
patients  with MS . The symptoms, which include a combination of cognitive, sensory and 
motor  manifestations, vary among patients and throughout the disease course according to the 
affected CNS areas  and the severity of the demyelinating attacks.  Approximately 85% of 
patients with MS have initially RRMS  (Multiple Sclerosis International Federation,  2013), 
which is characterized  by [CONTACT_470698] 
(relapses) and periods of remission, consisting of partial or  complete recovery (Lublin, 2014).  
The most important features of highly active RRMS include frequen t relapses with incomplete  
recovery, and/or high radiological burden of disease, rapid accrual of disability after disease 
onset,  with otherwise typi[INVESTIGATOR_470665] (Lublin, 2014). Data on the epi[INVESTIGATOR_470666] y the proportion of patients that are classified as 
highly active comes  from clinical trials. However, data show that around 14.4% to 14.8% of 
patients who had  experienced breakthrough disease activity (â‰¥  1 relapse in the 12 months 
prior to randomization ) (Gold, 2013; Rudick, 2006) and 22.2% of treatment -naÃ¯ve patients 
(Polman, 2006) met the criteria  for highly active RRMS (â‰¥2 relapses in the year prior to study 
entry and â‰¥  1 Gd+ lesion on T1 - weighted MRI at study entry) (Gold, 2013; Rudick, 2006; 
Polman,  2006).  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  25/84 
  Treatment and Management of  Relapsing Multiple Sclerosis  
Patients with relapsing MS ( RMS ) are recommended to receive treatment with DMD  to 
decrease the rate of relapse and slow the accumulation of brain lesions on MRI. Numerous 
immunomodulat ory agents with differing routes of administration and mechanisms of action 
have been shown to have beneficial effects. Because they are not curative, most DMD s are 
typi[INVESTIGATOR_470667]. There is cur rently 
no standard protocol to guide the choice of DMD s for patients with MS. Rather, treatment 
decisions and medication choices are the result of a thorough risk -benefit analysis and 
consideration of disease activity, patient -specific factors, and drug -related factors (Pardo , 
2017 ).  
Cladribine (2 -chloro -2'-deoxyadenosine [2 -CdA]) is a synthetic anti -neoplastic drug that 
belongs to the subgroup of agents called purine analog s. Cladribine Tablets have  been 
approved by [CONTACT_470699] 2017 for the treatment of adult MS patient with high active disease 
(see Section 2). 
CLARITY Clinical T rial ([STUDY_ID_REMOVED])  
In the Phase  III, multi -center , randomized , double -blind CLARITY clinical trial 
([STUDY_ID_REMOVED]), treatment with Cladribine Tablets demonstrated a significant reduction in 
the annualized  relapse rate (ARR) at [ADDRESS_603168] bo. 
This corresponded to an ARR risk reduction of 57.4% for the 3.5  mg/kg  dose. The reduction 
in ARR was also consistent across various patient subgroups, including those with highly 
active disease. Furthermore, the CLARITY study demonstrated that Cladribi ne Tablets were 
significantly superior to placebo in the treatment of RRMS across all clinical and MRI 
efficacy outcomes (Giovannoni, 2010).  
The CLARITY -EXT study showed that in patients who followed Cladribine Tablets with 
placebo , a substantial proporti on remained free from indicators of disease activity, regardless 
of prior active treatment in CLARITY. Overall rates of (clinical and MRI) disease activity -
free status were consistently high, although a longer treatment gap resulted in lower 
proportions of  patients with no new T1 Gd+ lesions compared with those who had a shorter 
treatment gap (Comi, 2018).  
ORACLE  MS Clinical Trial ([STUDY_ID_REMOVED])  
The ORACLE MS clinical trial ([STUDY_ID_REMOVED]) was a Phase III, randomi zed, double -blind, 
placebo -controlled, multicenter , triple arm trial to evaluate the safety and efficacy of 
Cladribine Tablets in patients with early disease who had experienced a first clinical 
demyelinating event (FCDE) and who were at high risk of converti ng to CDMS, according to 
Poser criteria. Patients taking Cladribine Tablets (3.5  mg/kg) demonstrated statistically 
significant differences to the placebo group in the time to CDMS conversion during the initial 
treatment period up to the data cut -off (Leist , 2014).  
Additionally, treatment with Cladribine Tablets significantly reduced the number of T1 Gd+ 
-enhanced lesions, new or enlarging T2 lesions, and combined unique active  MRI lesions 
compared with placebo  (Leist, 2014).  Cladribine Tablets were associa ted with clinical and 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  26/84 
  MRI improvements versus placebo in patients with early RRMS (time to second event), active 
RRMS, and patients who were experiencing relapses despi[INVESTIGATOR_470668] 
(Comi , 2013; Comi , 2016; Freedman , 2017; Giovannoni , 2010;  Giovannoni, 2016; 
Giovannoni , 2018 ; Leist , 2014 ; Montalban , 2016 ).  
Based on these clinical trial results, Cladribine Tablets were approved for the treatment of 
RRMS in several markets. However, following negative Committee for Medicinal Products 
for Huma n Use opi[INVESTIGATOR_166036] 2011 , [COMPANY_006] voluntarily withdrew further applications for approval 
as some regulatory authorities required more data to fully characterize  the drugâ€™s benefit -risk 
profile. Consequently, there are a number of patients who received Cladribine Tablets prior 
to the earlier withdrawal. These patients have been followed in MS registries and 
observational studies for safety outcomes. The PREMIERE (P rospective Observational Long -
term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine 
Clinical Studies) study evaluated the safety of Cladribine Tablets over 10,[ADDRESS_603169] of 2017, the European Commission granted marketing authorization for 
Mavenclad Â® (Cladribine Tablets) for the treatment of highly active relapsing MS. The clinical 
program for cladribine in MS included more than 10, 000 patient -years of data. This included 
8,650 patient -years of cladribine exposure and more than 2 ,000 patient -years of placebo 
exposure (Cook , 2016 ). 
Although the PREMIERE study provides long -term data following treatment with Cladribine 
Tablets, this s tudy primarily evaluated safety outcomes, and thus additional real -world data 
are needed to understand the long -term effects of Cladribine Tablets on key mea sures of 
disability progression and to address the knowledge gaps around treatment patterns of pati ents 
with MS in a clinical setting.  
2.3 Benefit/Risk Assessment  
The primary aim of this study is to generate evidence  regarding  long-term disability 
progression and  treatment sequencing following Cladribine Tablet treatment . Results from 
this study may be of b enefit to patients  with MS  and clinicians by [CONTACT_4205][INVESTIGATOR_470669] -making.  
As this study does not involve administration of any investigational medicinal product   
(IMP) , there are minimal risks to the patient s involved. Patients who come to the clinic will 
be asked to provide a n optional  blood sample for pharmacogenetics testing only if they 
consent to this additional sample and testing. Blood draws may cause discomfort, bruising 
and very rarely  infection at the site where the skin is punctured by [CONTACT_98847]. Patients may 
also experience dizziness, nausea or fainting durin g blood  sampling . However, in general 
these reactions are mild to moderate and will resolve on their own.  
Only a subset of study participants  will participate in the MRI (without gadolinium) sub-study  
at Study Visit  2, and steps have been taken to minimiz e risk to patient s participating in the 
MRI assessment by [CONTACT_470700] s who are pregnant due to the unknown risks 
regarding rare fetal and childhood adverse event ( AE) outcomes following ex posure to MRI 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  27/[ADDRESS_603170] protocol detailed 
in a separate MRI userâ€™s manual, with appropriate safety precautions i.e. not including patient s 
with MRI -incompatible metal in their body . 
There are no restrictions or instructions for permitted or pro hibited medicines for this study . 
Study participants will receive medicines according to  their usual care under their treating 
physician. Once study participants  have concluded their participation in this study, they will 
continue to be treated according t o their usual practice and care and their usual care will not 
be affected by [CONTACT_50568].  
Based on the available nonclinical and clinical data to date, the conduct of the study, as 
specified in this proto col, is considered justifiable.  
[ADDRESS_603171], and real -world treatment patterns following treatment with Cladribine 
Tablets or placebo among patients with MS who were part of the parent studies . The 
objectives of this study are  all exploratory and for hypothesis generating purposes.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  30/84 
  Exploratory Objectives  Endpoints (Outcome Measures)  
To assess durability of clinical o utcomes 
after treatment with IMP from Baseline (i.e. 
first doseb of IMP) to Study  Visit  1 in study 
participants previously treated with IMP as 
part of the Phase III ORACLE MS and 
CLARITY/CLARITY -EXT clinical trials.  Tertiary endpoints to be evaluated via 
retrospective data collection from medical 
records or at Study  Visit  1:  
â€¢ Proportion of study participants being 
bedriddend  
â€¢ Time from first doseb of IMP to first use of 
an ambulatory deviced 
â€¢ Time from first doseb of IMP to first use of 
a whee lchaird 
â€¢ Annualized Relapse Rate (ARR) from time 
of first doseb of IMP to Study  Visit  1, and 
by 2-year intervals  
â€¢ Time to conversion to Clinically Definite 
MS (CDMS) (For ORACLE MS study 
participants only)  
â€¢ Proportion of study participants diagnosed 
as Second ary Progressive MS (SPMS) 
without relapses in the 3  months prior to 
SPMS diagnosis  
â€¢ Proportion of study participants diagnosed 
as SPMS with relapses in the 3  months 
prior to SPMS diagnosis  
â€¢ Proportion of study participants diagnosed 
as Primary Progressive MS  (PPMS) (For 
ORACLE MS study participants only)  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  31/84 
  Exploratory Objectives  Endpoints (Outcome Measures)  
To assess impact on quality of life and 
cognitive outcomes after treatment with 
IMP during the period from the last clinical 
visit in the CLARITY/CLARITY -
EXT/ORACLE MS clinical trials to 
Study  Visit  1 in stu dy participants 
previously treated with IMP as part of the 
Phase  III ORACLE MS and 
CLARITY/CLARITY -EXT clinical trials.  Tertiary endpoints to be evaluated at 
Study  Visit  1:  
â€¢ Change in EuroQoL -5 Dimension 
Questionnaire (3 level version) (EQ -5D-
3L) 
â€¢ Change in cognition as measured by [CONTACT_470701] (to be collected  for 
ORACLE MS subjects only in countries 
where these instruments were used in the 
CLASSIC  MS study):   
o The Brief Visuospatial Memory Test â€“ 
Revised (BVMT -R) 
o Symbol Digit Modality Test (SDMT)  
To assess durability of outcome on brain 
imaging after treatment with IMP from 
Baseline (i.e. the last MRI before first doseb 
of IMP; if feasible, by [CONTACT_68089]) to within 3 
months  after Study Visit  1 in study 
participants previously treate d with IMP as 
part of the Phase  III ORACLE MS and 
CLARITY/CLARITY -EXT clinical trials.  ORACLE MS, CLARITY and CLARITY -
EXT study participants from selected sites 
will be invited to participate in a follow -up 
study visit (Study Visit  2) to take place 
within 3 months  (maximum [ADDRESS_603172] patient enrolled ) 
following Study  Visit  1, for evaluation of the 
following:  
Change in MRI assessment from Baseline 
(i.e. the last MRI before first doseb of IMP) 
to Study Visit  2 in:  
â€¢ Total volume of T2 lesions  
â€¢ Total number of T2 lesions  
â€¢ Number of hypointense lesions on T1 -spin 
echo MRI  
â€¢ Volume of hypointense lesions on T1 -spin 
echo MRI  
â€¢ Brain volume or surrogate (in cases where 
brain volume is not possible to assess for 
technical reasons, then 3rd ventricle 
diameter may be evaluated)  
â€¢ Ventricular volume  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  32/84 
  Exploratory Objectives  Endpoints (Outcome Measures)  
To determine whether the high -disease 
activity (HDA) patients from the 
CLARITY/CLARITY -EXT clinical trials 
are more likely to be the long -term 
responders.  Comparison of the responder rate in HDA 
patientse versus the responder rate in non -
HDA patients from the 
CLARITY/CLARITY -EXT population.  
To evaluate differences in genetics between 
long-term responders and study participants 
requiring alternate th erapi[INVESTIGATOR_470670]/CLARITY -EXT and ORACLE 
MS populations.  Correlation of genetic variations with long -
term responders (defined as study 
participants who did not demonstrate any 
evidence of disease reactivation based on 
Investigator assessment of clinical and 
imaging outcomes until Year [ADDRESS_603173] doseb 
of IMP) compared to other study participants 
who started on alternate therapy less than [ADDRESS_603174] doseb of IMP for 
the CLARITY/CLARITY -EXT and 
ORACLE MS populations.  
ARR =Annualized Relapse Rate , BVMT -R=Brief Visuospatial Memory Test Revised , CDMS =Clinically Definite 
Multiple Sclerosis , EDSS =Expanded Disability Status Scale , EQ-5D=EuroQoL -5 Dimension , HDA =High-disease 
activity , IMP=Investigational Medicinal Product , MRI=Magnetic Resonance Imaging , MS=Multiple Sclerosis , 
PPMS =Primary Progressive MS , RRMS =Relapsing -Remit ting Multiple Sclerosis , SDMT =Symbol Digit Modalities 
Test, SPMS =Secondary Progressive Multiple Sclerosis.  
a Specific clinical and demographic characteristics may include gender, age, race, ethnicity, education, disease 
duration, years previous disease mo difying treatment (before start of CLARITY/CLARITY -EXT/ORACLE MS) and 
disease classification (RRMS or SPMS).  
b One dose is equivalent to one tablet. One course of IMP is defined as 1 year of treatment with IMP (2 treatment  
cycles  [weeks]) . A treatment cycle is defined as daily administration of IMP given consecutively over 4 -5 days 
during a 28 -day period. One treatment week is equivalent to 1 treatment cycle.  
c Total volume of T2 lesions; Total number of T2 lesions; Number of hypointense lesio ns on T1 -spin echo MRI; 
Brain volume or surrogate; Ventricular volume.  
d Mobility endpoints may be determined via EDSS scores (if available) or corresponding clinical descriptions in 
medical records.  
e 1. Patients with â‰¥2 relapses during the year prior to parent study entry, regardless of prior disease modifying 
drugs (DMD) use; 2. Patients with â‰¥1 relapse in the previous year and â‰¥1 T1 Gd+ lesions or â‰¥9 T2 lesions, while 
on therapy with other DMDs.  
 
 
4 Study Design  
4.1 Overall Design  
This Phase IV , low-intervent ional,  multicenter , ambispe ctive study will involve  the evaluation 
of medical records of study participants  treated with Cladribine Tablets or placebo  (IMP)  in 
the previously  conducted parent studies . Long -term retrospective data will be collected 
through evaluation of medical charts/records, and additional prospective data will be 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  33/84 
  collected. No IMP will be administered as part of this study. An interim analysis is planned 
when data from approximately  100 patients are collected  (see Section 9 for further details on 
analyses ).  
This study will collect data from study participants  with MS who participated in the 
CLARITY/CLARITY -EXT  clinical  trial(s) and who received â‰¥  1 course of IMP, or study 
participants  with their FCDE  who were randomi zed in the ORACLE MS  study and received 
â‰¥ [ADDRESS_603175] visit is the Screening 
Visit. The following screening activities may be administered by [CONTACT_470702]/or not willing  to attend clinic for the visit , depend ing on approval by [CONTACT_470703]  (ECs), Institutional Review Boards  (IRB s), and/or local regulations:  Informed 
consent  (for patients participating in retrospective data collection  only, local requirements for 
patient consent will be observed, which may include informed consent form [ICF] waiver) , 
sociodemographic and clinical characteristics, medical and d isease history, and study  
inclusion/exclusion determination .  
Retrospective data for deceased  or lost to follow -up patients will be collected in case an  ICF 
waiver is granted,  or proxy/caregiver/legal representative consent is obtained, depending on 
approv al by [CONTACT_39989], IRBs, and/or local regulations.  
The second visit is Study Visit 1, which could be combined with the Screening Visit . At this 
visit retrospective data (from medical chart review) and current data will be collected . For 
patients who are able to at tend the visit at the clinic  data on  a physical assessment, Expanded 
Disability Status Scale (EDSS), Patient -Reported Outcomes (PROs) , cognitive assessments , 
AEs and concomitant medications  will be collected . For all patients the following  
retrospective data  will be collected:  EDSS, Secondary Progressive MS (SPMS)  conversion , 
details of subsequent DMDs , including physician questions on treatment decisions , date of 
first use of an ambulatory device or wheelchai r, date of first time bedridden and relapse history 
from end of parent study to Study Visit [ADDRESS_603176] the opportunity to provide pharmacogenetic samples after Study Visit 1 and up to 
6 months from Screening  (unless last pat ient enrolment has occurred , in which case the 
sample can only be collected at Study Visit 1 ). 
For patients from whom  in-person EDSS at clinic visit was not planned to be collected, a 
telephone EDSS  questionnaire  will be administered . Attempts should be made to administer 
the telephone EDSS  within 14 days after informed consent was received  for patients not 
attending the clinic visit.   
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  34/[ADDRESS_603177] clinical trial(s), which will 
be inte grated for milestones such as interim analyses and, if needed, on a regular basis. It is 
the Sponsor, not the site, that is responsible for obtaining the information from the past clinical 
trial(s) study databases. However, the sites will be requested to p rovide some patient 
identifiers (e.g. patient number, parent study patient participated in, year of birth and gender) 
to match data being collected with previous data set s.  
The third potential clinic visit is Study Visit 2, which involves an MRI scan with out 
gadoli nium  in approximately 150  patients who are willing to participate in this MRI sub-
study . The sites that participate in the MRI sub-study  will be selected primarily based on their 
technical capabilities to perform the required MRI assessments and the availability of the 
original MRI machine from the parent studies . The patients at these sites will be selected 
based on being able to fulfil l the eligibility criteria (see Section  [IP_ADDRESS] ), including the 
availability/consent of the patient to perform a new MRI  and the provision of a urine 
pregnancy test within a week prior to the MRI assessment  (for female patients of childbearing 
age). A serum pregnancy test is also acceptable if available as per standard of care ( SOC ). 
Verbal reporting  of pregnancy status by [CONTACT_470704] . AEs and 
concomitant medications will also be reviewed and recorded during this visit.  For patients 
who are not experiencing relapse at the time of screening, t he duration between  Screening  
Visit to Study Visit  1 is no more than 2 weeks, including for patients who are participating 
remotely and who are completing a telephone EDSS assessment only.  For patients 
experiencing relapse, the duration between Screening and Study Visit 1 is between 4 weeks 
and 3 months . For patients selected to participate in the MRI sub-study , an additional visit 
will be required that will occur within a maximum of 3 months  of Study Visit  1 (maximum [ADDRESS_603178] patient recruitment  has occurred ), and these patientsâ€™ total 
study duration will likely be no more than 3.5 months if the patient was not experiencing 
relapse at Screening, or up to 6 months  maximum  in the case of relapse .  For patients 
providing samples for p harmacogenetic testing , the time window for sample collection is up 
to a maximum  of 6 months from Screening (unless last patient enrolled has occurred, in which 
case the testing must occur at Study Visit 1) .    Sites will be asked to enter any retrospective 
data into the electronic case report form (eCRF) for this study within 12  weeks of enrolling  
the patient.  Participants who are eligible will be given the option of completing the screening, 
Study Visit  1, and 2 (where facilities for MRI are available) on the same day if prefer to do 
so and meet th e eligibility  criteria on that day (e.g. abstention from alcohol or cannabinoid 
products in the preceding  24 hours). Participants who are undergoing relapse or suspected 
relapse at the time of screening will be invited for Study Visit  [ADDRESS_603179] 
Visit  is expected in Q1 2021  (see Section 4.4 End of Study Definition ). 
Patient sel ection bias will be  addressed  through specific statistical methods  (see Section 9 for 
further details on statistical considerations). Site selection bias will be addressed  by [CONTACT_470705] .  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  35/[ADDRESS_603180], and real -
world treatment patterns in patients previously participating in the parent studies . This 
exploratory Phase IV study includes retrospective and prospective asses sments. It will involve 
the collection of long -term retrospective data through abstraction of medical charts/records. 
For patients participating in the prospective assessment of the study, additional data will be 
collected at Study Visit  1 and patients wil l be asked for an optional blood sample . For a subset 
of patients, an MRI assessment will be performed at Study Visit 2, which will occur within a 
maximum of 3 months  after completing Study Visit  1 (maximum [ADDRESS_603181] 
patient recruitment  has occurred ). No IMP will be administered as part of this study.  
The primary objective of this study is to evaluate long -term mobility after treatment with 
Cladribine Tablets or placebo in the parent studies . This will be evaluated by [CONTACT_470706], the p roportion of study participants using a wheelchair (defined as unable to walk 
beyond approximately 5 meters even with aid, essentially restricted to wheelchair; wheels self 
in standard wheelchair and transfers alone; up and about in wheelchair som e 12 hours a day) 
the majority of the time in the 3 months prior to Study Visit 1 or  participants are  bedridden 
any time prior to Study V isit 1, determined via  EDSS score of 7.0 or higher, or alternative 
clinical description data in medical records . This primary endpoint was selected as a reliable 
and valid measure of long -term mobility following treatment with  IMP in the parent studies . 
This endpoint was agreed upon by [CONTACT_470707], as u se of a wheelchair or being bedridden is a disability 
milestone for patients with MS and will likely be recorded in medical charts, either as a 
clinical description or via an EDSS score of 7 .0 or higher . This endpoint is also practical to 
evaluat e at Study Visit 1, thus maximi zing the amount of data that can be collected for the 
primary endpoint in this study.  
The secondary objective is the comparison of clinical characteristics between long -term 
responders ( defined as study participants who did not demonstrate any evidence of disease 
reactivation based on Investigator assessment of clinical and imaging outcomes until Year [ADDRESS_603182] dose of IMP ) compared to those who started on 
alternate therapy less than [ADDRESS_603183] dose of IMP for the combined parent 
study  populations. This secondary objective helps to fill an important data gap, which is 
understanding treatment sequencing following Cladribine Tablets and specifically 
understanding if there are differences in clinical characteristics (gender, age/year of birth, 
race, ethnicity, education, employment status, disease duration [years ], current disease 
modifying treatment, time since last relapse [months ], and disease classification [RRMS or 
SPMS])  between study participants who did and did not start on an alternative therapy within 
[ADDRESS_603184] dose of IMP in the parent studie s. 
The study will enroll  study participants  with MS who participated in the 
CLARITY/CLARITY -EXT clinical trials and who received â‰¥  1 course of IMP  (Cladribine  
Tablets or placebo) , or with their FCDE  who were randomized  in the ORACLE MS  study and 
received â‰¥  1 course of IMP  (Cladribine  Tablets or placebo) . Data collection for this study is 
based on study participants  recruited into previously  conducted clinical trials which had 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  36/84 
  defined inclusion and exclusion criteria. Therefore, the chosen inclusion criteria  (Section  5.1) 
aim to be as inclusive as possible to maximize the number of study participants  from the 
parent studies  who can be enrolled , while allowing for the patient or their 
proxy/caregiver/legal representative  (in cases where an ICF waiver  will not  apply)  to consent 
to allow the collection of retrospective data and/or prospective data  in order  to maximi ze the 
data that can be collecte d in this exploratory study. The chosen exclusion criteria  (Section  5.2) 
will protect the safety of study participants by [CONTACT_470708]. 
4.3 Justification for Dose  
Not Applicable.  
4.4 End of Study Definition  
A participant has completed the study if he/she has completed all study parts, including the 
last visit and/or the last scheduled procedure shown in Section  1.3 (Schedule of Activities).  
The end of the study is defined as the date of  the last patientâ€™s last visit.  For study participants 
taking part in the main study only  (i.e. for participants not participating in the MRI sub-study ), 
a participant has completed the s tudy if he/she has completed all study parts, including the 
Study Visit 1, which will be the last p atient â€™s last visit  collected for the study.  For those also 
taking part in the MRI sub-study , the Study Visit [ADDRESS_603185] study participantâ€™s  last 
visit.  
A clinical study protocol may not be considered closed as long as:   
â€¢ Visits specified by [CONTACT_216640], or  
â€¢ Procedures according to the protocol are still being undertaken in any patient . 
During study participation and  once patient s have concluded their participation in this study, 
they will continue to be treated as part of their usual practice and care.   
[ADDRESS_603186] received â‰¥  1 course of IMP (Cladribine Tablets or placebo) or patients 
with their FCDE randomi zed in the ORACLE MS  study who have received â‰¥  1 course of 
IMP.  
The criteria in Section s 5.1 (Inclusion Criteria) and 5.2 (Exclusion Criteria) are designed to 
enroll  only participants who are appropriate for the study; thereby, ensuring the study fulfil ls 
its objectives.  All relevant medical and nonmedical condi tions should be taken into 
consideration when deciding whether a participant is suitable for this study.  
Prospective approval of protocol deviations to inclusion and exclusion criteria, also known as 
protocol waivers or exemptions, is not permitted.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  37/84 
  Before  performing any study assessments that are not part of the participantâ€™s routine medical 
care, the Investigator will confirm that the participant or the participantâ€™s 
proxy /caregiver/legal representative has provided written informed consent, or an ICF wai ver 
is in place, if permitted  by [CONTACT_470709]/IRB . 
5.1 Inclusion Criteria  
Participants are eligible to be included in the study only if all the following criteria apply:  
1. Patients with MS randomized  in CLARITY/CLARITY -EXT clinical trial(s) who have 
received â‰¥  1 course of IMP (Cladribine Tablets or placebo) . 
or 
Patients with their FCDE  randomi zed in ORACLE MS  clinical trial who have received 
â‰¥ 1 course of IMP  (Cladribine Tablets or placebo) . 
Informed C onsent  
2. Can give signed informed consent, as indicated in Appendix 2 (Study Governance), 
which includes compliance with the requirements and restrictions listed in the ICF 
and this protocol. Data will be collected from the medical records of deceased or los t 
to follow -up patients  if consent is obtained by [CONTACT_3445]â€™s proxy/caregiver/legal 
representative  or if an ICF waiver is in place , if permitted by [CONTACT_470710]/IRB . 
5.2 Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:   
Medical Conditions  
Any condition, including any uncontrolled disease state other than MS, that in the 
Investigatorâ€™s opi[INVESTIGATOR_1649] , constitutes an inappropriate risk or a contraindication for participation 
in the study or that could interfere with the study objectives, conduct, or evaluation . If a patient 
is experiencing a confirmed or suspected relapse at the time of screening, the Medical Monitor 
is to be consulted to agree on a stabilization  period (estim ated to be between 4 weeks and 3 
months) before Study Visit  1. 
For specific exclusion criteria for the MRI sub -study please see Section [IP_ADDRESS]  (MRI Sub -
Study ). 
5.[ADDRESS_603187] any meal/dietary restrictions to specify.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  38/[ADDRESS_603188] any restrictions on participant activity level to 
specify.  
5.4 Screen Failures  
Individuals who do not meet the criteria for participation in this study (screen failure) may 
not be rescreened.  Patients with confirmed or suspected relapses can remain in the study , 
and Study Visit 1 will be postponed until the pa tient has stabili zed. 
6 Study Intervention(s)  
Study intervention is any investigational intervention(s), marketed product(s), placebo, or 
medical device(s) intended to be administered to a study participant per the study protocol.  
6.1 Study Intervention(s) Admin istration  
This study does not involve administration of any  IMP. Participants enrolled  will have 
participated in CLARITY/CLARITY -EXT and ORACLE MS  clinical trials, where they 
received  Cladribine Tablets or placebo according to those study protocols.  
6.1.1 Medical Device(s) Use  
Not Applicable.  No medical devices are provided for use in this study.  
6.2 Study Intervention(s) Preparation, Handling, Storage, and 
Accountability  
Not Applicable.   
6.3 Measures to Minimize Bias: Study Intervention 
Assignment and Blinding  
6.3.1 Study Intervention Assignment  
Not Applicable . 
6.3.2 Blinding  
Not Applicable . 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  39/[ADDRESS_603189] in the case report form ( CRF ) all concomitant therapi[INVESTIGATOR_014] (e.g., med icines or nondrug 
interventions) used from the time the participant signs the informed consent until completion 
of the study , including any changes. For prescription and over -the-counter medicines, 
vaccines, vitamins, and herbal supplements, record the nam e, reason for use, dates 
administered, and dosing information.  
The use of concomitant medications and therapi[INVESTIGATOR_470671]. The 
first sequential disease modifying MS therapy that was taken following treatment with 
Cladribine Ta blets, and the categorization  of the second sequential treatment following 
Cladribine Tablets ( categorized  by [CONTACT_470711][INVESTIGATOR_014], monoclonal antibody disease 
modifying treatments, oral disease modifying treatments, other, and unknown treatments)  will 
be assessed through retrospective review of the patientâ€™s medical records and captured as part 
of the CRF.  
Contact [CONTACT_470712].  
6.5.1 Rescue Medicine  
There are no restrictions or instructions for rescue medicines for participants in this study. 
Participants will receive medicines as part of their usual care by [CONTACT_24018].   
6.5.2 Permitted Medicines  
There are no restrictions or instructions for p ermitted medicines for participants in this study. 
Participants will receive medicines as part of their usual care under their treating physician.  
6.5.3 Prohibited Medicines  
There are no prohibited medicines  in this study.  Study participants  will receive medicines as 
part of their usual care under their treating physician.  
6.5.4 Other Interventions  
[IP_ADDRESS]  Optional Blood Sampling for Pharmacogenetics Testing  
Patients willing to consent to provide a n optional  blood sample and who are seen at a site with 
available capabilities to store and ship samples will have a blood draw taken at Study Visit 1 
for pharmacogenetics  testing.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  40/84 
  [IP_ADDRESS]  MRI Sub -Study  
The population to be included in the MRI sub -study will be based on the availability/consent 
of the patient to perform a new MRI, availability of the original machine and other technical 
site capabilities that will be defined following assessment of site feasibility to conduct the 
MRI sub -study.  
For study participants at select ed sites where MRI assessments will be conduct ed, the 
following exclusion criteria will apply to the MRI assessment only:1  
a. Female study participants who are pregnant2  
b. Patient s were administered Cladribine Tablets through prescription or as part of 
another study within  6 month period before enrolment in the MRI Sub -study (i.e. 
patients participating in a clinical trial or observational study within the 6 month 
period before enrolment in the MRI Sub -study,  but do not receive Cladribine Tablets 
as part of these studies , are allowe d to participate in the sub -study).  
Patients willing to provide their consent to participate in the MRI sub-study  and who do not 
meet any of the above exclusion criteria will have an MRI without g adoli nium taken.  Any 
MRI scan will be performed according to a standard protocol detailed in a separate MRI scan 
userâ€™s manual. A central neuroradiology center will perform the analysis of all MRI scans. As 
with other laboratory tests and clinical measures, strict adherenc e to the MRI scanning 
protocol and prompt handling of the scans is essential in obtaining a meaningful result. A 
urine pregnancy test will be conducted in female patients  of childbearing potential  
participating in the MRI sub -study within a week prior to t he MRI assessment. A serum 
pregnancy test is also acceptable if available as per SOC. Verbal reporting of pregnancy status 
by [CONTACT_470704].  For pregnant female patients the MRI visit may be 
rescheduled for a later date (within the t imeframes specified in  Section  4.1) following 
pregnancy outcome.  
Prior to patient assessment, each study site will be asked to send a â€˜testâ€™ or â€˜dry -runâ€™ scan to 
assess image quality and shipment procedures, to evaluate the accessibility of the electronic 
data carrier, and to assess the ability to correctly reposition patients to get comparable brain 
images. Only upon final approval of this test scan, sites will be al lowed to begin assessing 
patients. Once patients are enrolled , the quality of the scans will be assessed as soon as 
possible, as part of an ongoing quality control procedure. Investigators will be informed about 
the acceptance of scans and the need for sca ns to be repeated due to protocol deviations.  
                                                 
 
 
1 If patient is not eligible for MRI, MRI will not be performed but clinical data for other objectives may be 
collected.  
2 Due to unknown risks regarding rare foetal and childhood adverse event outcomes following exposure to MRI 
during pregnancy (Ray, 2016) , MRI procedures will not be performed for female patients who are pregnant, but 
may be scheduled for a later follow up date followi ng pregnancy outcome . 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  41/[ADDRESS_603190]  to the applicable local laws and regulations, patient s who cannot participate or 
complete  the SoA due to cognitive impairment or relapsing epi[INVESTIGATOR_470672]/caregiver/legal representative providing consent on their behalf.   
Study visits for participants  who are relapsing can be postponed until it is appropriate for them  
to complete study visit assessments. The decision to postpone the study visit will be made at 
the discretion of the physician based on the ability of the pati ent to attend the clinic and 
complete the assessments without causing discomfort or harm to the patient.  
6.[ADDRESS_603191] (AESIs) for this study as defined in the SmPC should be 
considered as a me dically significant AE and reported to the Sponsor using a Serious Adverse 
Event (SAE) Report Form with all related information.  
Three main categories of  AEs were defined as  AESI:  
â€¢ Severe (â‰¥  Grade  3) lymphopenia: Lymphopenia is an expected event based on th e 
mechanism of action of cladribine, an adenosine deaminase -resistant analog  of 
deoxyadenosine, that after conversion to its active triphosphate form (2 -Cd-ATP), 
decreases peripheral lymphocyte counts;  grading should be performed according 
Common Terminolo gy Criteria for Adverse Events  where Grade 3  is defined as 
< 500/mm3- 200/mm3. 
â€¢ Infections: Defects in cell -mediated immunity and immunosuppressive conditions 
may predispose patients to infectious diseases . 
â€¢ Malignancies: Immunodeficiency could lead to an increased risk for the development 
of malignancies; however, this is generally seen where immunosuppression is 
profound and long-lasting . Malignancy cases have been reported in MS patients 
treated with other DMDs. In view of these considerations the potential risk of 
malignancy for Cladribine Tablets  has been thoroughly evaluated.  
 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  42/84 
  7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
7.1 Discontinuation of Study Intervention  
Not Applica ble. 
7.1.1 Temporary Discontinuation  
Not Applicable.  
7.1.2 Rechallenge  
Not Applicable.  
7.2 Participant Discontinuation/Withdrawal from the Study  
â€¢ A participant  may withdraw from the study at any time, at his/her own request (i.e., 
withdrawal of consent), and without giving  a reason.  
â€¢ Patientsâ€™ proxy/caregiver/legal representative may withdraw consent at any time as well, 
without giving a reason.  
â€¢ For the MRI sub -study, t he participant may be withdrawn by [CONTACT_470713] . 
â€¢ The participant may be withdrawn at any time at the discretion of the Investigator for 
safety, behavioral , or administrative reasons.  
â€¢ The SoA specifies the data to collect at each follow -up visit, and any additional evaluations 
that need to be completed.  These assessments are not mandatory,  and patients can remain 
in the study if certain assessments (e.g. PROs) are not completed.  
â€¢ Partic ipants can withdraw consent for the optional pharmacogenetic testing any time; this 
does not preclude them from continuing in the study and complete other assessments.  
The patient will be informed that  any data collected from the signature [CONTACT_470751] t 
until the point of withdrawal will be maintained and included in the analysis (pending review 
and approval by [CONTACT_39989], IRBs and/or local regulations  and patient consent ). The Investigator 
should make every attempt to clarify the level of withdrawal: e. g., if the participant can still 
be contact[CONTACT_470714]/her status (e.g., alive or not). In case of withdrawal 
from the study, the appropriate CRF section must be completed.  
If a participant withdraws consent from the optional pharmacogene tic testing before the 
samples have been analyzed , the participantâ€™s samples will be destroyed without being 
analyzed . In addition, data collected will be excluded from the analysis. If a participant  
withdraws from the pharmacogenetic testing after the par ticipantâ€™s sample has been analyzed , 
any information learned from the analysis will remain part of the study database and may not 
be removed.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  43/84 
  Participants  or their proxy/caregiver/legal representative  will be informed that they have the 
right to withdraw f rom the study at any time, without prejudice to their medical care, and that 
they are not obliged to state their reasons. Any withdrawal must be fully documented in the 
eCRF and source documents and  should be followed up by [CONTACT_737]. The Investigat or 
may withdraw a patient  at any time if this is considered to be in the patient â€™s best interest.  
Participants who are discont inued/withdrawn from the study will not be replaced.   
7.[ADDRESS_603192] be taken if a participant fails to return to the clinic for a required 
study visit:  
â€¢ The site must attempt to contact [CONTACT_172055], counsel the participant on the importance of maintaining the assigned visit 
schedule and  ascertain if the participant wants to or should continue in the study.  
â€¢ Before a participan t is deemed â€œlost to follow -upâ€, the Investigator or designee must 
make every effort to regain contact [CONTACT_6635]: 1) where possible, make 
3 telephone calls; 2) if necessary, send a certified letter (or an equivalent local method) 
to the particip antâ€™s last known mailing address, and 3) if a participant has given the 
appropriate consent, contact [CONTACT_2299]â€™s general practitioner for information. These 
contact [CONTACT_13140]â€™s medical record.  
â€¢ Should the partici pant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
8 Study Assessments and Procedures  
â€¢ Study assessments and procedures and their timing are summarized in Section 1.3 
(Schedule of Activities ). 
â€¢ No protocol waivers or exemptions are allowed.  
â€¢ Immediate safety concerns should be discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue the study . 
â€¢ Adherence to the study design requirements, including those specified in the SoA, is 
essential  and required  for study conduct.  
â€¢ All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log 
to record details of all participants screened, to confirm eligibility, and if applicable, 
record reasons for screening failure.   
â€¢ Prior to performing any study assessments that are not part of the participantâ€™s routine 
medical care  or before e ntering data in the study electronic data capture ( EDC ) system , 
the Investigator will confirm that the participant or the participantâ€™s 
proxy/caregiver/legal representative has provided informed consent . Data will be 
collected from the medical records of d eceased or lost to follow -up patients  if consent 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  44/84 
  is obtained by [CONTACT_3445]â€™s proxy/caregiver/legal representative  or an ICF waiver is in 
place, if permitted by [CONTACT_470709]/IRB.  
â€¢ Procedures conducted as part of the part icipantâ€™s routine medical care (e.g., pregnancy 
test for MRI sub -study ) and obtained before signing of the ICF may be used for 
screening or baseline purposes provided the procedures met the protocol -specified 
criteria and were performed within the time fra me defined in the SoA.  
8.1 Efficacy Assessments and Procedures  
A detailed schedule of study procedures/assessments is provided in  the SoA  (Section 1.3). 
During the  Screening  Visit, the patient  or their proxy/caregiver/legal representative will be 
informed of the study objectives and overall requirements, and informed consent will be 
obtained prior to any study specific assessments , unless an ICF waiver is in place  (see 
Appendix 2  Study Governance  for details on informed consent process) . The site will 
also confirm that patients meet the Inclusion/Exclusion C riteria. During th is visit, a complete 
Screening Evaluation will be performed, which will capture socio demographic  and clinical  
characteristics (including gender, age /year of birth , race  and ethnicity  where permitted , 
employment status and education level attained), medical history, and disease history 
(including classification of disease and diagnosis date).  These screening activities may be 
administered by [CONTACT_470715] , 
dependent on approval by [CONTACT_39989], IRBs, and/or local regulations . For patients participating only 
in retrospective data collection, local requirements for patient consent will be observed, which 
may include informed consent waiver .  
PRO questionnaires , follo wed by [CONTACT_470716] (for ORACLE MS  patients only),  
should be performed prior to any other assessments.   
For patients participating in the MRI assessment, attempts should be made to perform 
Study  Visit 2 within 3 months  (maximum)  after completing Study Visit  1 (maximum [ADDRESS_603193] patient has been recruited ). A urine pregnancy test will be 
performed within a week prior to the MRI assessment  in female patients of childbearing 
potential . A serum pregnan cy test is also acceptable if available as per SOC . Verbal reporting 
of pregnancy status  by [CONTACT_470717]. The Investigator will ensure that the 
patient or the patientâ€™s proxy/caregiver/legal representative has provided specific informed 
consent to participate in MRI assessments.  
8.1.1 Clinical Endpoints  
[IP_ADDRESS]  Expanded Disability Status Scale ( EDSS ) 
The EDSS is a neurological  assessment that will be used to assess the long -term disability 
progression following treatment with IMP in the parent studies  (Appendix 5Expanded 
Disability Status Scale (E DSS)). EDSS is a scale from 0 -10 that evaluates a person with MS â€™s 
disability/neurologic function level with 6  being the critical point at which a patient requires 
ambulatory assistance.  The primary endpoint of proportion of study participants using a 
wheelchair (defined as unable to walk beyond approximately 5 meters even with aid, 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  45/84 
  essentially restricted to wheel chair; wheels self in standard wheelchair and transfers alone; up 
and about in wheelchair some 12  hours a day) the majority of the time in the 3 months prior 
to Study Visit 1 or participants are bedridden any time prior to Study Visit 1 determined via 
an EDSS score of 7.0 or higher (if available), or alternative clinical description data in medical 
records . The secondary endpoint will be determined as the  proportion of study participants 
with EDSS of 6.[ADDRESS_603194] disease activity rather than disease progre ssion (Healy, 
2013) ; an EDSS measurement taken a t a single point in time may be subject to measurement 
error (Goodkin, 199 2). As such, confirmation of sustained EDSS score is needed to mitigate 
against measurement error and EDSS fluctuation (Kalinci k, 2015) .  
Furthermore , while EDSS scores at any time point , regardless of their relationship to relapses , 
may serve as evidence of EDSS progression, it is generally  recommended that only EDSS 
scores that are recorded more than 30 days from the onset of a preceding relapse be used in 
order to confirm progression events (Kalincik, 2015) . As such, Investigators in this study will 
be instructed to exclude any EDSS score recorded within 30 days of a previous relapse.  
The in-person EDSS will be completed by [CONTACT_470718] 1. Alternatively, a  telephone  EDSS 
score can be determined by [CONTACT_470719]  (Lechner -Scott, 2003) . The telephone EDSS 
will be collected only from patients not attending clinic visits, and will be collected within 14 
days of obtaining informed consent. Only one mode of the collection (in -person during  a clinic 
visit, or by [CONTACT_756]) is required per pati ent. Retrospective EDSS scores will be ascertained 
from medical records  for the time period between  end of parent study to Study Visit 1 (when 
available) .  
Reasons for inability to come to the clinic for  Study Visit 1 may include travel/migration , or 
limit ed mobility (bedridden) , or clinical site restrictions due to COVID -19. In addition, 
patient s may not want to come to the clinic for Study Visit [ADDRESS_603195] .. 
[IP_ADDRESS]  EDSS Confidence Scale  
For each EDSS score that is obtained retrospectively from m edical charts and at the time of 
Study Visit 1, the evaluating physician will be asked to complete the EDSS Confidence Scale 
which is a single question indicating their confidence in that scoreâ€™s accuracy . This will be 
based on a non -validated 4 -point Likert  scale where 0 = not at all confident and 3 = highly 
confident.   
[IP_ADDRESS]  Bedridden Status  
A patientâ€™s status as being bedridden will be determined by [CONTACT_470720] 8.0 or higher 
(â€œessentially restricted to bed or chair or perambulated in wheelchair but  may be out of bed 
itself much of the dayâ€) , if available , or by [CONTACT_470721].  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  46/84 
  [IP_ADDRESS]  Subsequent Disease Modifying Drugs and T reatment 
Decisions  
Details of subsequent DMDs , including physician questions on treatment decisions  will be 
captured in the eCRF , based on chart review to determine the time, type, and reason for the 
first sequential treatment after the first course of Cladribine Tablets and the categorization  of 
the second sequential treatment ( categori zed by [CONTACT_470711][INVESTIGATOR_014], monoclonal 
antibody disease modifying treatments, oral disease modifying treatme nts, other , and 
unknown treatments).   
[IP_ADDRESS]  First Use of Ambulatory Device  
The date of first use of ambulatory device will be determined through retrospective chart 
review, based on  an EDSS score of 6.0  or higher (score of 6.0 is defined as â€œintermittent or 
unilateral constant assistance [cane, crutch, brace ] required to walk about 100 meters with or 
without restingâ€) or clinical descriptions if EDSS scores are not available.  
[IP_ADDRESS]  First Use of Wheelchair  
The date of firs t use of a wheelchair will be determined through retrospective chart review, 
based on an EDSS score of 7.0  or higher (score of 7.0 is defined as unable to walk beyond 
approximately 5  meters even with aid, essentially restricted to wheelchair; wheels self i n 
standard wheelchair and transfers alone; up and about in wheelchair some 12  hours a day ) or 
clinical descriptions if EDSS scores are not available.  
[IP_ADDRESS]  Relapse Count  
The following information on relapses will be recorded on the relapse module of the eCRF , 
if available : the number of relapses from  end of parent study  to Study Visit  1; relapse onset 
date and stabilization/resolution date; estimated relapse duration; maximal EDSS at time of 
relapse (if known); major systems affected; treatment required for rela pse; patient  
hospi[INVESTIGATOR_470673]; o utcome of relapse  (i.e. increase in disability ). A relapse will be 
defined as patient -reported symptoms and objectively observed signs typi[INVESTIGATOR_470674] , developi[INVESTIGATOR_162408] -acutely, with 
duration of at least 24 hours, in the absence of fever or infection (Thompson, 2018) . 
[IP_ADDRESS]  Conversion to C linically Definite Multiple Sclerosis  
(ORACLE MS  Participants Only )  
Conversion to CDMS will be determined according to the McDonald 2017 criteria 
(Thompson, 2018 ; Table 2). For more details please see Appendix 6 2017 Mc Donald 
Criteria  (From Thompson, 2018) ). 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  47/84 
   
Table 2 The 2017 McDonald criteria for diagnosis of Multiple Sclerosis in 
patients with an attack at onset  
Clinical Presentation  Additional Data Needed to Make MS Diagnosis  
â€¢ â‰¥2 attacks and objective 
clinical evidence of â‰¥2 
lesions  
â€¢ â‰¥2 attacks and objective 
clinical evidence of 1 
lesion with historical 
evidence of prior attack 
involving lesion in 
different location  None. Dissemination in space (DIS) and dissemination in 
time (DIT) have been met.  
â€¢ â‰¥2 attacks and objective 
clinical evi dence of 1 
lesion  
 One of these criteria:  
â€¢ DIS: additional clinical attack implicating different CNS 
site 
â€¢ DIS: â‰¥1 symptomatic or asymptomatic MS -typi[INVESTIGATOR_2855] T2 
lesions in â‰¥2 areas of CNS: periventricular, 
juxtacortical/cortical, infratentorial or spi[INVESTIGATOR_1831] 
 
â€¢ 1 attack and objective 
clinical evidence of â‰¥2 
lesions  One of these criteria:  
â€¢ DIT: additional clinical attack  
â€¢ DIT: simultaneous presence of both enhancing and non -
enhancing symptomatic or asymptomatic MS -typi[INVESTIGATOR_470675]  
â€¢ DIT: new T2 or enhancing MRI lesion compared to 
baseline scan (without regard to timing of baseline scan)  
â€¢ Cerebrospi[INVESTIGATOR_872] ( CSF)-specific (i.e. not in serum) 
oligoclonal bands  
â€¢ 1 attack and objective 
clinical evidence of 1 
lesion  One of these criteria:  
â€¢ DIS: additional  attack implicating different CNS site  
â€¢ DIS: â‰¥1 MS -typi[INVESTIGATOR_470676] T2 
lesions in â‰¥2 areas of CNS: periventricular, 
juxtacortical/cortical, infratentorial or spi[INVESTIGATOR_470677]:  
â€¢ DIT: additional clinical attack  
â€¢ DIT: simultaneous presence of both enhancing and non -
enhancing symptomatic or asymptomatic MS -typi[INVESTIGATOR_470675]  
â€¢ DIT: new T2 or enhancing MRI lesion compared to 
baseline scan (without regard to timing of baseline scan)  
â€¢ CSF-specific (i.e. not in serum) oligoclonal bands  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  48/84 
   
[IP_ADDRESS]  Diagnosis of Secondary Progressive M ultiple Sclerosis  
Without Relapses  
SPMS without relapses will be defined as follows (Lublin, 2014; Kap pos, 2018) : 
â€¢ Documented moderate -to-advanced disability indicated by [CONTACT_470722] 3.0 â€“6.5 at 
time of diagnosis of SPMS  
â€¢ A history of RMS diagnosis  
â€¢ Documented at least 6  months sustained EDSS progression based on clinical 
judgment  
â€¢ Without  evidence of relapses in the 3  months before SPMS diagnosis  
Conversion to SPMS will be ascertained by [CONTACT_470723]  1 (for study participants  who may have 
converted to SPMS between last regular clinic visit and Study Visit  1). 
[IP_ADDRESS]  Diagnosis of Secondary Progressive M ultiple Sclerosis  
With Relapses  
SPMS with relapses will be defined as follows (Lublin, 2014; Kappos, 2018) : 
â€¢ Documented moderate -to-advanced disability indicated by [CONTACT_470722] 3.0 â€“6.5 at 
time of d iagnosis of SPMS  
â€¢ A history of RMS  diagnosis  
â€¢ Documented at least 6  months sustained EDSS progression based on clinical 
judgment  
â€¢ With evidence of relapses in the 3  months before SPMS diagnosis  
Conversion to SPMS will be ascertained by [CONTACT_470723]  1 (for study participants who may have 
converted to SPMS between last regular clinic visit and Study Visit  1). 
[IP_ADDRESS]  Diagnosis of Primary Progressive M ultiple Sclerosis  
(ORACL E MS Participants Only)  
As per the McDonald 2017 criteria ( Thompson, 2018 ), PPMS  can be diagnosed in patients 
with:  
â€¢ One year of disability progression (retrospectively or prospectively determined) 
independent of clinical relapse  
 
Plus 2 of the following cr iteria:  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  49/84 
  â€¢ One or more T2 -hyperintense lesions3 characteristic of multiple sclerosis in one or 
more of the following brain regions: periventricular, cortical or juxtacortical, or 
infratentorial  
â€¢ Two or more T2 -hyperintense lesions3 in the spi[INVESTIGATOR_1831]  
â€¢ Presence of cerebrospi[INVESTIGATOR_872] ( CSF) -specific oligo clonal bands  
[IP_ADDRESS]  Cognition Endpoints  (ORACLE MS Participants Only)  
Cognition measures to be administered at Study Visit  1 are as follows:  
â€¢ The Brief Visuospatial Memory Test â€“ Revised (BVMT -R) 
â€¢ Symbol Digit Modality Test (SDMT)  
Note that the BVMT -R and SDMT assessments are to be  collected  for ORACLE MS subjects 
only in countries where these instruments were used in the CLASSIC MS study .  
[IP_ADDRESS]  Brain Imaging  
A subset of study participants from the  parent studies  will be invited to participate in a fo llow-
up study visit (Study Visit  2) for an MRI assessment without gadolinium, to evaluate  the 
following parameters associated with chronic disease activity in MS patients :  
o Total volume of T2 lesions  
o Total number of T2 lesions  
o Number of hypointense lesio ns on T1 -spin echo MRI  
o Volume of hypointense lesions on T1 -spin echo MRI  
o Brain volume or surrogate ( In cases where brain volume is not possible to assess 
for technical reasons, then 3rd ventricle diameter may be evaluated)  
o Ventricular volume  
8.1.2 Other Assessments  
[IP_ADDRESS]  Patient -reported Outcomes/Quality of Life : EQ -5D-3L 
The 3-level version of the EuroQoL -5 Dimension questionnaire (EQ -5D-3L) will be 
administered at Study Visit 1. The EQ -5D-3L is a validated, self -administered, generic, utility 
instrument that includes 5 single -item dimensions: mobility, self -care, usual activities, 
                                                 
 
 
3 Unlike the 2010 McDonald criteria, no distinction between symptomatic and asymptomatic MRI lesions is 
required.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  50/84 
  pain/discomfort , and anxiety/depression (EuroQoL  Group, 1990) . Study participants  must 
choose between 3 levels of difficulty in accomplishing tasks in each dimension. The 
questionnaire also contains a Visual Analog Scale for the study participants  to rate their 
current health state from 0 (worst imag inable health state) to 100 (best imaginable health 
state).  
[IP_ADDRESS]  Frequency of Stable P atient Monitoring Questions   
Each evaluating physician at the clinical sites will be asked to complete questions  assess ing 
how frequently the study patients with MS are monitored and evaluated at their site in regular 
clinical practice. These questions  ask about frequency of follow -up visits  and follow -up MRI 
assessments if the study patients with MS are considered stable.  
8.2 Safety Assessments and Procedures  
The safety profile of th is study â€™s intervention s will be assessed through the recording, 
reporting and analysis of medical conditi ons, AEs, physical examination findings, and vital 
signs  as specified in the SoA (Section  1.3). A comprehensive assessment of any potential AE 
experienced by [CONTACT_470724]. The Investigator will report any AE, whether 
observed by [CONTACT_108098]; the reporting period is specified 
in Section 8.3.1  (Time Period and Frequency for Collecting Adverse Event and S erious 
Adverse Event  Information) .  
All clinically significant abnormalities occurring before signature [CONTACT_470752]/or Disease History; all abnormalities occurring 
or worsening after signature [CONTACT_470753] [CONTACT_760].  
There are no specific safety endp oints included in this study.  
8.2.1 Physical Examinations  
â€¢ A complete physical examination will include, at a minimum, assessments of the 
Cardiovascular, Respi[INVESTIGATOR_696], Gastrointestinal and Neurological systems.  Height and 
weight will also be measured and recorded.  
â€¢ A brief physical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular system, and abdomen (liver and spleen).  
â€¢ Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
8.2.2 Vital Signs  
Vital signs will be assessed and interpreted as per SOC . 
â€¢ Oral temperature, pulse rate, respi[INVESTIGATOR_697], and blood pressure will be assessed.  
â€¢ Blood pressure and pulse measurements will be assessed with a completely automated 
device. Manual techniques will  be used only if an automated device is not available.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  51/84 
  â€¢ Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_603196] 
for the participant in a quiet setting without distractions (e.g., television, cell phones).  
â€¢ Vital signs will be m easured in a semi -supi[INVESTIGATOR_55848] [ADDRESS_603197] readings should be averaged to give the measurement 
to be recorded in the CRF.  
8.2.3 Electrocardiograms  
Not Applicable.  
8.2.4 Clinical Safety Laboratory Assessments  
Not Applicable.   
8.2.5 Suicidal Risk Monitoring  
Not Applicable.  
8.3 Adverse Events and Serious Adverse  Events  
The definitions of an A E and a SAE  are in Appendix 3 (Adverse Events: Definitions and 
Procedures for Recording, Evaluating, Follow -up, and Reporting ). 
8.3.1 Time Period and Frequency for Collecting Adverse Event 
and Serious Adverse Event Information  
The AE reporting period for safety surveillance begins when the participant is initially 
included in the study ( i.e. date of first signature [CONTACT_43998]) and continues until  Study 
Visit  1 or, if applicable , Study Visit  2. 
All SAEs will be collected and reported as indicated i n Appendix 3 from the signing of the 
informed consent form until study Visit 1 or, if applicable, Study Visit 2. Beyond this 
reporting period if investigator learns of any SAE at any time after a participant has been 
discharged from the study, and he/she c onsiders the event to be reasonably related to the study 
intervention or study participation, the Investigator will promptly notify the Sponsor.   
Please note, in addition to any AE/SAE which occurs after informed consent, a ny adverse 
drug reaction (ADR) t hat occurred after the End of Trial Visit in the parent study and is 
assessed as related to Cladribine Tablets  by [CONTACT_470725].  
The method of recording, evaluating, and assessing causality of AEs (including SAEs) an d 
the procedures for completing and transmitting SAE reports are in Appendix 3. 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  52/84 
  8.3.2 Method of Detecting Adverse Events and Serious Adverse 
Events  
At each study visit, the  participant will be queried on changes in his or her condition. During 
the reporting period, any unfavorable  changes in the participantâ€™s condition will be recorded 
as AEs, regardless if reported by [CONTACT_470726]/legal representative  or 
observed by [CONTACT_737].  
Complete, accurate and consistent data on all AEs experienced for the duration of the 
reporting period (defined above ) will be reported on an ongoing basis in the appropriate 
section  of the CRF . All SAEs  must be additionally documented and reported using the 
appropriate Report Form as specified in Appendix 3. 
Due to the interventio nal nature of the MRI examination  that is done specifically for the 
purpose of this study , the study  specific procedure of A Es and S AEs data collection and 
reporting will be followed. The Sponsorâ€™s responsibilities regarding safety reporting will be 
carrie d out in accordance to the European Directive 2001/20/EC and with the related detailed 
guidance documents.   
8.3.3 Follow -up of Adverse Events and Serious Adverse Events  
AEs are recorded and assessed continuously throughout the study , as specified in Section 
8.3.1  (Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event 
Information) and are assessed for their outcome at the patientâ€™s last visit (i.e. Study Visit  1 for 
patients not participating in the MRI sub -study or Study Visit  2 for patients participating in 
the MRI sub -study). All SAEs ongoing at the  patientâ€™s last visit  must be monitored and 
followed up by [CONTACT_737] u ntil stabilization or until the outcome is known, unless the 
participant is documented as â€œlost to follow -upâ€. Reasonable attempts to obtain this 
information must be made and documented. It is also the responsibility of the Investigator to 
ensure that any necessary additional therapeutic measures and follow -up procedures are 
performed. Further information on follow -up procedures is given in Appendix 3 (Adverse 
Events: Definitions and Procedures for Recording, Evaluating, Follow -up, and Reports) . 
8.3.[ADDRESS_603198] comply with any applicable site -specific requirements related to the 
reporting of SAEs (particularly deaths) involving study participants to the Independent Ethics 
Committee ( IEC)/IRB that approved the  study.  
In accordance with International Conference on Harmoni sation ( ICH) Good Clinical Practice 
(GCP ), the Sponsor/designee will inform the Investigator of findings that could adversely 
affect the safety of participants, impact the conduct of the study or alter the IECâ€™s/IRBâ€™s 
approval/ favorable  opi[INVESTIGATOR_43932].  In line with respective regulations, the 
Sponsor/designee will inform the Investigator of AEs that are both serious and unexpected 
and considered to be related to the administ ered product (â€œsuspected unexpected serious 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  53/84 
  adverse reactionsâ€ or S[LOCATION_003]Rs). The Investigator should place copi[INVESTIGATOR_470678]. National regulations regarding Safety Report notifications to 
Investigators will be considered.  
When specifically required by [CONTACT_43973], the Sponsor/designee will provide 
appropriate Safety Reports directly to the concerned lead IEC/IRB and will maintain records 
of these notifications. When direct reporting is not clearly defined by  [CONTACT_108103] -specific 
regulations, the Investigator will be responsible for promptly notifying the concerned 
IEC/IRB of any Safety Reports provided by [CONTACT_1034]/designee and of filing copi[INVESTIGATOR_470679] e. 
For studies covered by [CONTACT_43975] 2001/20/EC, the Sponsorâ€™s responsibilities 
regarding the reporting of SAEs/S[LOCATION_003]Rs/Safety Issues will be carried out in accordance with 
that Directive and with the related detailed guidance documents.  
8.3.5 Pregnan cy 
All pregnancies of female participants occurring during the Adver se Event Reporting Period, 
defined in Section 8.3.1  (Time Period and Frequency for Collecting A dverse Event and 
Serious Adverse Event  Information) , must be recorded in the AE page/section of the CRF.  
For female participants in the MRI sub -study  with an estimated conception date during the 
safety surveillance period (Section  8.3.1 ), the Investigator must notify the Sponsor/designee 
in an expedited manner of any pregnancy using the Pregnancy Report Form, which must be 
transmitted by [CONTACT_250000] 3, section on  
Reporting Serious Adverse Events  and AESIs . Investigators must actively follow up, 
document and report on the outcome of all these pregnancies  (among MRI sub -study 
participants, as described above) , even if the participants are withdrawn from the study.  The 
Investigator must notify the Sponsor/designee of the outcomes of pregnancies among MRI 
sub-study participants using the Pregnancy Report Form. If an abnormal outcome occurs, the 
SAE Report Form will be used if the participant sustains an event and the Parent -Child/ Fetus  
Adverse Event Report Form if the child/ fetus  sustains an event. Any abnormal outcome  (e.g., 
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) must  
be reported in an expedited manner, as specified in Section  8.3.[ADDRESS_603199] be reported within 45 days after delivery.  
8.4 Treatment of Overdose  
Not Applicable.   
8.5 Pharmacokinetics  
Not Applicable.   
8.6 Pharmacodynamics  
Not Applicable.   
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  54/84 
  8.7 Pharmacogenetics  
Optional blood samples for pharmacogenetics testing will be collected at Study Visit  1 or 
during following  clinic  visits as per SoA (Section  1.3). 
â€¢ Where local regulations and IRB/IEC allow, an 8ml blood sample will be collected for 
DNA analysis from consenting participants. Participation in pharmacogenetic research is 
optional. Participants who do not wish to participate in the pharmacogenetic research 
may still participate in the study.  
â€¢ In the  event of DNA extraction failure, a replacement for pharmacogenetic testing may 
be requested from the participant. Additional informed consent will not be required to 
obtain a replacement sample.  
â€¢ Appendix 4 provides further information on pharmacogenetic research.  
8.8 Biomarkers  
Not Applicable.   
8.9 Immunogenicity Assessments  
No Applicable.   
8.10 Health Economics   
Not Applicable.  
9 Statistical Considerations  
One interim and 1 final analysis are planned for this study.  
Study data will be integrated with study data from the parent studies as required to perform 
the statistical analyses.  
Generally, data will be analyzed  descriptively with the following measures: mean with 
standard deviation, median with interquartile range, minimum and maximum for continuous 
variables and counts with percentages for categorical variables. Missing data will also be 
summarized . Patientsâ€™ d emographic factors and cl inical characteristics at enrol ment will be 
summarized descriptively as detailed above.  
As the study visits are around 10 years after the initial treatment with IMP in the parent 
studies, it is likely that only a specific type of participants from these trials is available for 
follow -up. A potential selection bias will be evaluated by [CONTACT_470727].  
Methodological approache s which evaluate and address this potential selection bias will be 
further detailed in the Statistical Analysis Plan (SAP). Differences in study populations will 
be considered when making inferences based upon study results. With this in mind, analyses 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  55/84 
  will generally be exploratory and for hypothesis generating purposes. Parameter estimates 
with associated 95% confidence intervals ( CIs) will be reported for the study endpoints, as 
appropriate  
The analytical approach for all endpoints is described below and will be further detailed in 
the integrated Analysis Plan (iAP).  
All procedures outlined within this section will be undertaken using a SAS statistical analysis 
software (version 9.4 or higher).  
9.1 Statistical Hypotheses  
No formal statistical hypothesis will be tested, as the study is designed to be exploratory.  
9.2 Sample Size Determination  
No formal sample size calculation has been made for this exploratory study as enrolment is 
limited to eligible study participants from the parent studies  (N=1,958). Therefore , as many 
study participants as feasibly possible will be enrolled  from this group.  
Using East Version 6, based on proportions of study participants that could be expected to be 
in a wheelchair (5%, 10% and 15%), and a range of sample size (30%, 40%, 50% and 60% 
participants recruited from the 1 ,958 participants in the parent studies ), the  following 
precision  (half-width) could be achieved for the 95% CI:  
% recruited  Sample Size  Proportion (Ï€)  95% CI  Half-width  
30 587 5% [3.52 ; 6.48]  1.48%  
30 587 10% [7.97 ; 12.03]  2.03%  
30 587 15% [12.58 ; 17.42]  2.42%  
40 783 5% [3.82 ; 6.18]  1.18%  
40 783 10% [8.37 ; 11.63]  1.63%  
40 783 15% [13.06 ; 16.94]  1.94%  
50 979 5% [4.03 ; 5.97]  0.97%  
50 979 10% [8.67 ; 11.33]  1.33%  
50 979 15% [13.42 ; 16.58]  1.58%  
60 1175  5% [4.21 ; 5.79]  0.79%  
60 1175  10% [8.92 ; 11.08]  1.08%  
60 1175  15% [13.71 ; 16.29]  1.29%  
9.3 Populations for Analyses  
The analysis populations are specified below. Four patient cohorts will be used for the purpose 
of exploring all objectives of the study protocol. These will include:  
â€¢ Cohort A : Patients who meet both the protocol inclusion and exclusion criteria and are 
drawn from the pooled CLARITY, CLARITY -EXT and ORACLE  MS clinical trials  
â€¢ Cohort B : Patients who meet both the protocol inclusion and exclusion criteria and are 
drawn from the CLARITY or CLARITY -EXT study only  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  56/84 
  â€¢ Cohort C:  Patients who meet both the protocol inclusion and exclusion criteria and are 
drawn from the CLARITY -EXT study only  
â€¢ Cohort D:  Patients who meet both the pro tocol inclusion and exclusion criteria and are 
drawn from the ORACLE MS study only  
The statistical analyses will generally be performed for Cohort A except for the secondary 
and tertiary endpoints unique to the parent studies , which will be analyzed  using study 
participants from these parent studies  only. The primary and selected secondary or tertiary 
analyses may be repeated by [CONTACT_133075] B, C and D in order to evaluate consistency of results 
across clinical trials.  
The following subgroups will be defined:  
Subgroup/Subset  Description  
Subgroup Treatment 
Course in Cohort B  â€¢ Study participants who received placebo only (i.e. study 
participants that received placebo in CLARITY  who did 
not enter CLARITY -EXT  or received placebo in both 
CLARITY and CLARITY -EXT ) 
â€¢ Study participants who received at least 1 dosea of 
Cladribine Tablets during either CLARITY or CLARITY -
EXT but did not start the 2nd year treatment coursea of 
Cladribine Tablets  
â€¢ Study participants who received at least [ADDRESS_603200] -year treatment 
course of Cladribine treatment  
â€¢ Study participants who received at least 1 dosea of 
Cladribine Tablets during CLARITY and CLARITY -
EXT that started >  2 treatment coursesa of Cladribine 
Tablets (i.e. patients who completed CLARITY and 
started at least the 1st year treatment coursea in 
CLARITY -EXT) . This corresponds to completing 
[ADDRESS_603201] 
course of Cladribine treatment.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  57/84 
  Subgroup/Subset  Description  
Subset Long -term 
Responder  Study participants  
â€¢ not requiring DMD until Year [ADDRESS_603202] 
dosea of IMP, and who did not demonstrate any evidence of 
disease reactivation based on Investigator assessment of 
clinical and imaging outcomes  
â€¢ who started on alternate therapy (DM D) less than [ADDRESS_603203] dosea of IMP  or who demonstrate  any 
evidence of disease reactivation based on Investigator 
assessment of clinical and imaging outcomes.  
Subset Types of 
Subsequent DMDs  â€¢ Platform injectable therapy (Interferon -Î² [AvonexÂ®, RebifÂ®, 
BetaferonÂ®, ExtaviaÂ®, PlegridyÂ®] or gla tiramer acetate 
[CopaxoneÂ®]) 
â€¢ Monoclonal antibody disease modifying treatment  
â€¢ Oral disease modifying treatment  
â€¢ Other subsequent treatment  
â€¢ Off-label treatments (drugs not approved by [CONTACT_470728])  
â€¢ No subsequent treatment  
Subgroup Prior Us e 
of DMD  â€¢ Prior use of DMD at any time in the patient's history before 
enrolment into CLARITY  
â€¢ Complementary subgroup  
Subgroup HDA for 
Cohort B  â€¢ HDA study participants  
â€¢ Non-HDA study participants  
DMD =disease -modifying drug , HDA =high disease activity , MS=multiple sclerosis . 
a One dose is equivalent to one tablet.  One course  of IMP  is defined as 1 year of treatment with IMP (2 
treatment cycles  [weeks ]. A treatment cycle is defined as daily administration of IMP given consecutively 
over 4 -5 days during a 28-day period. One treatment week is equivalent to 1 treatment cycle.  
The primary and selected secondary or tertiary analyses may be repeated by [CONTACT_470729]/subsets in order to evaluate the pattern of response.  
It should be noted that the subgroup ana lyses on the subgroupsâ€™ treatment courses and 
subsequent DMD do not support the comparison of any treatment effect as the definition of 
subgroups already is not independent from randomized treatment.  
9.4 Statistical Analyses  
The primary endpoint of this study  will be evaluated by [CONTACT_470730] 
95% CI of patients using a wheelchair  the majority of the time  in the 3 months prior to 
Study Visit 1 or patients bedridden any time prior to Visit 1  (as defined in Section  [IP_ADDRESS] ) 
for each Cohort and the appropriate subgroups/subsets as defined above in Section 9.3. 
Forest plots will also be used to display these results.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  58/84 
  In addition, proportions adjusted for participation in previous parent studies , as well as other 
patient characteristics which are deemed to be prognostic for the primary endpoint will be 
determined applying a logistic regression model. Variables with multiple levels of discrete 
values will be model ed as categorical variables, and variables with continuous scales (e.g. 
age) may be model ed as a continuous covariate or categori zed where appro priate.  
The secondary endpoint, the proportion of patients with EDSS of 6.[ADDRESS_603204] IMP  
from parent study.  will be presented together with the correspon ding 95% CI for each Cohort 
and appropriate subgroups/subsets as defined above. The results of the confidence scale of 
EDSS values will be presented descriptively and may be used to interpret ED SS results .  
The clinical and MRI characteristics of study par ticipants will be evaluated descriptively by 
[CONTACT_470731] -term responders for Cohort A. 
Tertiary endpoints collected retrospectively or at Study Visit  [ADDRESS_603205] clinical visit in the parent studies  to Study 
Visit  2 will be analyzed  descriptively.  
In addition, responder r ates in high-disease activity (HDA)  patients versus the responder rate 
in non -HDA patients from the CLARITY/CLARITY -EXT population will be analyzed  
descriptively.  
Time -to-event data will be calculated from first dose of IMP in the parent study and will be 
presented using Kaplan -Meier estimates or cumulative incidence curves as appropriate. The 
analytical approach will be further detailed in the SAP. 
Genetic variations will be analyzed  descriptively. In addition, association of genetic variations 
with patients experiencing long -term response will be analyzed . 
Adverse events will be summarized by [CONTACT_470732].  
 
Endpoint  Statistical Analysis Meth ods 
Primary  Percentage and 95% CI  
Secondary  Percentage and 95% CI  
Tertiary/Exploratory  Descriptive statistics and time-to-event analyses as described above  
9.4.1 Handling of Missing Data  
It is anticipated that missing data will feature within the available dataset for the many of the 
endpoints, particularly those that are collected through retrospective medical chart review. 
Subsequently, should missing values constitute a substantial proportion of the endpoint data  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  59/84 
  then multiple imputation may be used in addition to the complete case approach. The multiple 
imputation may be repeated applying different assumptions (missing at random, missing not 
at random).  
9.4.2 Sequence of Analyses  
An interim analysis is planned  to publish results  when  data from a minimum of 100 of pa tients 
is available from Cohort A. This data includes the primary and  key secondary endpoints as  
well as the EQ -5D-3L; pharmacogenetics and MRI will not be included in the interim 
analysis . Specifics will be detailed in the  iAP. Due to the exploratory nature of the study, an 
adjustment for multiple comparisons  is not required . 
The final analysis will be performed after final database lock.  
  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  60/[ADDRESS_603206] T, Comi G,  et al. Cladribine tablets in the treatment of p atients with multiple 
sclerosis: an integrated analysis of infections in association with severe lymphopenia. 
ECTRIMS Online Library, n. 146475, 2016.  
Comi G, Cook S D, Giovannoni G,  et al. MRI outcomes with cladribine tablets for multiple 
sclerosis in the CLARITY study. 2013. J Neurol ; 260 (4):  1136 -46. 
Comi G, Giovannoni G, Cook S,  et al. Magnetic resonance imaging (MRI) outcomes in 
patients with relapsing -remitting multiple sclerosis (RRMS) treated with cladribine tablets: 
results from the 120-week phase IIIb extension of the CLARITY study. Poster presented at: 
68th American Academy of Neurology Annual Meeting; April 15 -21, 2016; Vancouver, BC, 
Canada. Poster P2.114.  
Comi G, Cook S, Rammohan K,  et al. Long -term effects of cladribine tablets on MRI activity 
outcomes in patients with relapsing -remitting multiple sclerosis: the CLARITY Extension 
study. Ther Adv Neurol Disord . Jan 2018 ; 11.  
Dua T, Rompani P . Atlas: Multiple sclerosis resources in the world, 2008. Retrieved 10/15/18, 
from http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf . 
EuroQol Group . EuroQol -a new facility for the measurement of health -related quality of life. 
Health Policy . 1990; 16(3):  199-208. 
Freedman MS, Leist T, Comi G,  et al. The efficacy of cladribine tablets in CIS patients 
retrospectively assigned the diagnosis of MS using modern criteria: Results from the 
ORACLE -MS study. Mult Scler J Exp Transl Clin . 2017 ; 3(4) : 1-4. 
Giovannoni G, C omi G, Cook S,  et al. A placebo -controlled trial of oral cladribine for 
relapsing multiple sclerosis. N Engl J Med . 2010 ; 362(5) : 416-26. 
Giovannoni G, Comi G, Cook S,  et al. Benefits of cladribine tablets on the proportion of 
patients with multiple sclero sis free from clinical and radiological indicators of disease 
activity in the CLARITY EXTENSION study. ECTRIMIS Online Library, n. 146476, 2016.  
Giovannoni G, Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients 
with relapsing -remitting multiple sclerosis: Results from the randomized extension trial of the 
CLARITY study. Mult Scler . 2018; 24(12):  1594 -1604.  
Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high -yield process in relapsing -remitting 
multiple sclerosis (SELECT): a r andomised, double -blind, placebo -controlled trial. Lancet . 
2013; 381(9884): 2167 -75.  
Goodkin D, Cookfair D, Wende K,  et al. Inter - and intrarater scoring agreement using grades 
1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Scl erosis 
Collaborative Research Group. Neurology .1992; ; 42(4):  859-63.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  61/84 
  Healy B, Engler D, Glanz B,  et al. Assessment of Definitions of Sustained Disease 
Progression in Relapsing -Remitting Multiple Sclerosis. Multiple Sclerosis International . 
2013; 2013 : 9.  
Kalincik T, Cutter G, Spelman T,  et al. Defining reliable disability outcomes in multiple 
sclerosis. Brain  Nov 2015; 138(11): 3287 -98.  
Kappos L, Bar -Or A, Cree B,  et al. Siponimod versus placebo in secondary progressive 
multiple sclerosis (EXPAND): a double -blind, randomised, phase 3 study. Lancet . 2018; 
391([ZIP_CODE]): 1263 -1273.  
Kingwell E, Marriott J, Jette N,  et al. Incidence and prevalence of multiple sclerosis in Europe: 
a systematic review. BMC Neurol . Sep 2013; 13:128 . 
Lechner -Scott J, Kappos L, H ofman M,  et al. Can the Expanded Disability Status Scale be 
assessed by [CONTACT_756]? Mult Scler . 2003; 9(2): 154-9. 
Leist T, Comi G, Cree B, et al. Effect of oral cladribine on time to conversion to clinically 
definite multiple sclerosis in patients with a f irst demyelinating event (ORACLE MS): a phase 
3 randomised trial. Lancet Neurology . 2014  ; 13(3):  257-267.  
Lublin F, Reingold S, Cohen J, et al. Defining the clinical course of multiple sclerosis: the 
2013 revisions. Neurology . 2014; 83(3): 278-86. 
Montal ban X, Cohen B, Leist T, et al . Efficacy of cladribine tablets as add -on to IFN -beta 
therapy in patients with active relapsing MS: final results from the phase II ONWARD study. 
Poster presented at: 68th American Academy of Neurology Annual Meeting; April 1 5-21, 
2016; Vancouver, BC, Canada. Poster P3.029.  
Multiple Sclerosis International Federation . Atlas of MS 2013. Mappi[INVESTIGATOR_470680]. Retrieved 1/25/19, from https://www.msif.org/wp -
content/uploads/2014/09/Atlas -of-MS.pdf  
Noseworthy  J, Lucchinetti C, Rodriguez M,  et al. Multiple Sclerosis. N Engl J Med . Sep 2000; 
343(13): 938-52. 
Pardo G, Jones DE . The sequence of disease -modifying therapi[INVESTIGATOR_470681]: safety and immunologic considerations. J Neurol . 2017  ; 264(2):  2351 -74. 
Polman C, Oâ€™Connor P, Havrdova E,  et al. A randomized, placebo -controlled trial of 
natalizumab for relapsing multiple sclerosis. N Engl J Med . 2006; 354:  899-910. 
Przybek J, Gniatkowska I, Mirowska -Guzel D,  et al. Evolution of diagn ostic criteria for 
multiple sclerosis. Neurol Neurochir Pol . 2015; 45(5):  313-21. 
Ray J, Vermeulen M, Bharatha A,  et al. Association  between MRI exposure during pregnancy 
and fetal and childhood outcomes. JAMA . 2016; 316(9):  952-61.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  62/84 
  Rudick R, Stuart W, C alabresi P, et al. Natalizumab plus interferon beta -1a for relapsing 
multiple sclerosis. N Engl J Med . Mar 2006; 354(9):  911-23. 
Scalfari A, Knappertz V, Cutter G,  et al. Mortality in patients with multiple sclerosis. 
Neurology . Jul 2013; 81(2):  184-192. 
Thompson A, Banwell B, Barkhof F,  et al. Diagnosis of multiple sclerosis: 2017 revisions of 
the McDonald criteria. Lancet Neurol . 2018; 17(2): 162-173. 
Tramacere I, Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for 
relapsing -remitting multiple sclerosis: a network meta -analysis. Cochrane Database Syst Rev . 
2015; 9: CD011381.  
Wallin M, Culpepper W, Campbell J,  et al. The prevalence of multiple sclerosis in the United 
States: a population -based healthcare database approach. Multiple Sclerosis Journal . 2017 ; 
23(S3): 85-426. 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  63/[ADDRESS_603207] â€“ Revised  
CDMS  Clinically Definite Multiple Sclerosis  
CI Confidence Intervals  
CNS  Central Nervous System  
CRF  Case Report Form  
CSF Cerebrospi[INVESTIGATOR_470682]-5D-3L EuroQoL -5 Dimension Questionnaire (3 level version)  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  64/[ADDRESS_603208] of Care  
SPMS  Secondary Progressive Multiple Sclerosis  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  65/84 
  S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reactions  
 
 
 
  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  66/84 
  Appendix 2  Study Governance  
Financial Disclosure  
Investigators and Sub -Investigators will provide the Sponsor with sufficient, accurate 
financial information, as requested, for the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
This information is required during the study and for 1 ye ar after completion of the study.  
Informed Consent Process  
â€¢ A study main informed consent  will be provided to patients or their 
proxy/caregiver/legal representative  and this will cover both Screening and study 
participation . The informed consent  requires a wet ink signature .  
o For deceased or lost to follow -up patients, the informed consent  may be obtained 
from proxy/caregiver/legal representative, or an informed consent form ( ICF) 
waiver  will apply, dependent on approval by [CONTACT_470733], Institutional 
Review Boards, and/or local regulations.  
â€¢ A separate  informed consent  will be provided for optional pharmacogenetic testing, 
including collection and storage of a n optional  blood sample . This informed consent  
will need to be completed  at the site.   
â€¢ Patients participating in the MRI sub-study  will be provided with a separate informed 
consent  for the sub-study . This informed consent  will need to be completed  at the site.  
â€¢ The Investigator or his/her representative will explain the nature of the study to the 
participant or his/her proxy/caregiver/legal representative  and answer all questions  on 
the study.  
â€¢ Participants must be informed that their participation is voluntary.  
â€¢ Participants or their legally -authori zed representative (defined as proxy or caregiver) 
will be required to sign a statement of informed consent that meets the requirements of 
local regulations; International Council for Harmonisation  (ICH) guidelines; Heal th 
Insurance Portability and Accountability Act (HIPAA) requirements, where applicable; 
and the Institutional Review Board ( IRB)/Independent Ethics Committee ( IEC) or study 
center.  
â€¢ The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled  in the study and the date the written consent 
was obtained. For written informed consent, t he authorized person obtaining the 
informe d consent must also sign the ICF.  
â€¢ If the ICF is updated during their participation in the study, participants must be re -
consented to the most current, approved version , if still on the study . 
â€¢ A copy  of the ICF(s)  (or an original, signed ICF in applicable countries)  must be 
provided to the participant or the participantâ€™s proxy/caregiver/legal representative . 
6XEVWDQFHFRGH1$ &/$66,&06
06B
 
7KHRULJLQDOVLJQH GDQGGDWHGFRQVHQWZLOOU HPDLQDWWKH,QYHVW LJDWRUÂ¶VVLWHDQGPXVWEH
VDIHO\DUFKLYHGVRWKDWLWFDQEHUHWULHYHGDWDQ\WLPHIRUPRQ LWRULQJDXGLWLQJDQG
LQVSHFWLRQSXUSRVHV
x3DUWLFLSDQWVZKRDUHUHVFUHHQ HGDUHUHTXLUHGWR VLJQDQHZ,&) 
'DWD3URWHFWLRQ
x7KH6SRQVRUZLOODVVLJQDXQLTXHLGHQWLILHUWRSDUWLFLSDQWVDIW HUREWDLQLQJWKHLULQIRUPHG
FRQVHQW$OOSDUWLFLSDQWUHFRUGVRUGDWDVHWVWUDQVIHUUHGWRWKH 6SRQVRUZLOOFRQWDLQWKH
LGHQWLILHURQO\SDUWLFLSDQWQDPHVRUDQ\LGHQWLILDEOHLQIRUPDW LRQZLOOQRWEHWUDQVIHUUHG
x7KH6SRQVRUPXVWLQIRUPSDUWLFLSDQWVWKDWWKHLUSHUVRQDOVWXG\ UHODWHGGDWDZLOOEHXVHG
SHUORFDOGDWDSURWHFWLRQ DQGSULYDF\ODZV7KHOHYHORIGLVFOR VXUHPXVWDOVREH
H[SODLQHGWRWKHSDUWLFLSDQW
x7KHSDUWLFLSDQWPXVWEHLQIRUPH GWKDWKLVKHUPHGLFDOUHFRUGVP D\EHH[DPLQHGE\
&OLQLFDO4XDOLW\$VVXUDQFHDXGLWRUVRURWKHU6SRQVRUDSSRLQWHG DXWKRUL]HGSHUVRQQHO
E\DSSURSULDWH,5%,(&PHPEHUVDQGE\UHJXODWRU\DXWKRULW\LQV SHFWRUV$OOVXFK
SHUVRQVZLOOVWULFWO\PDLQWDLQSDUWLFLSDQWVÂ¶FRQILGHQWLDOLW\
6WXG\$GPLQLVWUDWLYH
x7KHVWXG\DLPVWRLQYROYHDSSUR[LPDWHO\VLWHVLQFRXQWUL HVDFURVV1RUWK$PHULFD
(XURSHDQG$VLD3DFLILF
6LWHVWKDWSDUWLFLSDWHGLQ&/$5,7<&/$5,7<(;7RU25$&/(06ZL OOEHLQYLWHGWR
SDUWLFLSDWHLQWKLVVWXG\
x7KH6WHHULQJ&RPPLWWHHPHPEHUVOLVWHGRQWKHWLWOHSDJHUHSUHVH QWDOO,QYHVWLJDWRUVIRU
GHFLVLRQVDQGGLVFXVVLRQVRQWKLVVWXG\SHU,&+*RRG&OLQLFDO 3UDFWLFHV*&3V7KH
6WHHULQJ&RPPLWWHHPHPEHUVZLOOSURYLGHH[SHUWPHGLFDOLQSXWDQ GDGYLFHRQWKHVWXG\
GHVLJQDQGH[HFXWLRQDQGLVUHVSRQVLEOHIRUWKHUHYLHZDQGVLJQ RIIRIWKHFOLQLFDOVWXG\
UHSRUW
x7KHVWXG\ZLOODSSHDULQWKHIROORZLQJFOLQLFDOVWXGLHVUHJLVWU LHVFOLQLFDOWULDOVJRY
x7KHFRQWUDFWUHVHDUFKRUJDQL]DWLRQWDVNHGZLWKVWXG\PDQDJHPHQW UHJXODWRU\DQGVWDUWXS
PRQLWRULQJHSLGHPLRORJ\DQGPH GLFDOZULWLQJGDWDPDQDJHPHQW VDIHW\PDQDJHPHQW
FOLQLFDOHYHQWYDOLGDWLRQDQGDGMXGLFDWLRQVHUYLFHV DQGFHQWUDOODERUDWRU\IRUVWRUDJHRI
SKDUPDFRJHQHWLFVDPSOHVLV,49,$ %URRN'ULYH*UHHQ3DUN 5HDGLQJ%HUNVKLUH
5*888QLWHG.LQJGRP
x7KHWKLUGSDUW\VHUYLFHSURYLGHUWDVNHGIRU05,VXEVWXG\VHWX SDQGTXDOLW\FRQWURORI
LPDJLQJ FROOHFWHG IRU WKH VXEVWXG\ LV %,2&/,1,&$  &DUQHJLH  &HQWHU 'ULYH
3ULQFHWRQ1HZ-HUVH\86$
x7KHWKLUGSDUW\VHUYLFHSURYLGHUWDVNHGIRU05,FHQWUDOUHDGLQJ RILPDJLQJFROOHFWHGIRU
WKHVXEVWXG\LV6,(1$,0$*,1*9LD)LRUHQWLQDÂ±Â±6LHQ D6,,WDO\
x7KHWKLUG SDUW\VHUYLFHSURYLGHUWDVNHGIRU%907 5FHQWUDOUHDGLQJRIWKHUHVSHFWLYH
FRJQLWLYHWH VWLQJFROOHFWHGIRUWKHVWXG\LV 
[COMPANY_003]
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  68/84 
  â€¢ The third -party service provider tasked for Biostatistical services on the stud y is Cytel Inc. 
([ADDRESS_603209], Cambridge, MA [ZIP_CODE], [LOCATION_003]).   
â€¢ Responsibilities regarding safety and medical monitoring are described in the Safety 
Monitoring Plan and the Medical Monitoring Plan, respectively. Details of structures and 
associated procedures will be defined in a separate Study Reference Manual.  
Regula tory and Ethical Considerations  
â€¢ This study will be conducted in accordance with the protocol and the following:  
o Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and Council for International Organiza tions of Medical 
Sciences  International Ethical Guidelines  
o Applicable ICH GCP Guidelines  
o Applicable laws and regulations  
â€¢ The Investigator must submit the protocol, protocol amendments (if applicable), ICF, 
summary of product characteristics ( SmPC ), and oth er relevant documents (e.g., 
advertisements) to an IRB/IEC and the IRB/IEC must review and approve them before 
the study is initiated.  
â€¢ Any protocol amendments (i.e., changes to the protocol) will be documented in writing 
and require IRB/IEC approval before  implementation of changes, except for changes 
necessary to eliminate an immediate hazard to study participants. When applicable, 
amendments will be submitted to the appropriate Health Authorities.  
â€¢ The Investigator will be responsible for the following:  
o Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently per the IRBâ€™s/IECâ€™s requirements, policies, and procedures  
o Notifying the IRB/IEC of serious adverse event s (SAEs ) or other significant safety 
findings, as requi red by [CONTACT_1744]/IEC procedures  
o Providing oversight of the study conduct at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical 
studies (if applicable), and all other applicable local regulatio ns 
â€¢ The protocol and any applicable documentation will be submitted or notified to the 
Health Authorities in accordance with all local and national regulations for each site.  
Clinical Study Insurance and Compensation to Participants  
Insurance coverage will be provided for each country participating in the study. Insurance 
conditions shall meet good local standards, as applicable.  
Clinical Study Report  
After study completion, the Sponsor or delegate will write a clinical study report in 
consultation with the Steering Committee or other relevant study -appointed committees or 
groups . 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  69/84 
  Publication  
â€¢ The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the Investigator agrees to submit all manuscripts or abstracts to th e Sponsor 
before submission. This allows [COMPANY_006] to protect proprietary information and to provide 
comments.  
â€¢ The Sponsor will comply with the requirements for publication of study results. Per 
standard editorial and ethical practice, the Sponsor will genera lly support publication of 
multicenter  studies only in their entirety and not as individual site data. In this case, a 
Coordinating Investigator [INVESTIGATOR_249969].  
â€¢ Authorship will be determined by [CONTACT_470734].  
Dissemination of Clinical Study Data  
â€¢ After completion of the study, a Clinical Study Report (including results on all study 
objectives except , in case not available  in time , results of the pharmacogenetic testing) 
according to ICH Topic E3 will be written by [CONTACT_470735].  
â€¢ Analyses of pharmacogenetics testing  will be completed approximately 2 years after 
study completion and will be presented in a clinical study report addendum , if not 
reported in the Clinical Study Report . 
â€¢ The Investigators will inform the Sponsor in advance of any plans to publish or present 
data from the study. Any publications and presentations of the results (abstracts in 
journals or ne wspapers, oral presentations etc.), either in whole or in part, by 
[CONTACT_152506] -submission review by [CONTACT_1034].  
â€¢ The Sponsor will not suppress or veto publications but  maintains the right to delay 
publication in order to protect intellectual property rights.  
â€¢ The study will be posted on clinicaltrials.gov.  
Data Quality Assurance  
â€¢ All participant study data will be recorded on electronic case report form (e CRFs ) or 
transmitted to the Sponsor or designee electronicall y (e.g., laboratory data). The 
Investigator is responsible for verifying that data entries are complete, accurate, legible, 
and timely by [CONTACT_175064] ( CRF ). Details 
for managing CRFs are in the Study Reference Manual.  
â€¢ For PRO data (e.g., QoL and cognitive assessments), paper PRO will be used.  
â€¢ The Investigator must maintain accurate documentation (source data) that supports the 
information in the CRF.  
â€¢ The Investigator must permit study -related monitoring, quality  assurance audits, 
IRB/IEC review, and regulatory agency inspections and provide direct access to the 
study file and source data.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  70/84 
  â€¢ Monitoring details describing strategy (e.g., risk -based initiatives in operations and 
quality such as Risk Management and Mit igation Strategies and Analytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site 
monitoring) are in the Monitoring Plan.  
â€¢ The Sponsor or d esignee is responsible for data management of this study, including 
quality checking of the data and maintaining a validated database. Database lock will 
occur once quality control and quality assurance procedures have been completed.  
â€¢ Study monitors will perform ongoing source data verification to confirm that data in the 
CRF are accurate, complete, and verifiable; that the safety and rights of participants are 
being protected; and that the study is being conducted per the currently approved 
protocol and a ny other study agreements, ICH GCP, and all applicable regulatory 
requirements.  
â€¢ Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by [CONTACT_13177] 15 years after study completion, unless local 
regulations, institutional policies, or the Sponsor requires a longer retention. No records 
may be destroyed during the retention period without the Sponsorâ€™s written approval. 
No records may be transferred to another location or party without the Sponsorâ€™s w ritten 
notification.  
Source Documents  
â€¢ Source documents provide evidence for the existence of the participant and substantiate 
the integrity of the data collected.  
â€¢ The Investigator must keep a paper or electronic file (medical file and original medical 
records) at the site for each study participant. The file must identify each participant, 
contain the following demographic and medical information for the participant, and 
should be as complete as possible:  
â€¢ Participantâ€™s full name, date of birth, sex, height,  and weight  
â€¢ Medical history and concomitant diseases  
â€¢ Prior and concomitant therapi[INVESTIGATOR_014] (including changes during the study)  
â€¢ Study identifier (i.e. , the Sponsorâ€™s study number) and participantâ€™s study number  
â€¢ Dates of entry into the study (i.e., signature [CONTACT_108167]) and each 
visit to the site  
â€¢ Any medical examinations and clinical findings predefined in the protocol  
â€¢ All AEs  
â€¢ Date that the participant left the study, including any reason for early withdrawal 
from the study or study intervention, if applicable  
â€¢ All source data must be filed (e.g., CT or MRI scan images, ECG recordings, and 
laboratory results). Each document must have the participant number and the procedure 
date; ideally, printed by [CONTACT_470736]. As necessary, medical 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  71/84 
  evaluation of these records should be performed, documented, signed and dated by [CONTACT_3786].  
â€¢ Data recorded on printed or electronic CRFs that are transcribed from source documents 
must be consistent with the source doc uments or the discrepancies must be explained. 
The Investigator may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available.  
â€¢ The study monitors will use printouts of electronic f iles for source data verification. 
These printouts must be signed and dated by [CONTACT_470737].  
â€¢ Source documents are stored at the site for the longest possible time permitted by [CONTACT_233589], and/or as per ICH GCP  guidelines, whichever is longer. The 
Investigator ensure s that no destruction of medical records is performed without the 
Sponsorâ€™s written approval.  
â€¢ Definition of what constitutes source data is found in  the Monitoring P lan. 
Study and Site  Start and  Clos ure 
â€¢ The study start date is the date when the clinical study will be open for recruitment.  
â€¢ The first act of recruitment is when the site first activated  and opened to recruitment,  and 
will be the study start date.  
â€¢ The Sponsor reserves the right to close th e study site or terminate the study at any time 
and for any reason. Study sites will be closed upon study completion. A study site is 
considered closed when all required documents and study supplies have been collected 
and a site closure visit has been com pleted.  
â€¢ The Investigator may initiate site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
â€¢ Reasons for the early closure of a study site by [CONTACT_470738]: 
â€¢ Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local Health Authorities, the Sponsor's procedures, or GCP guidelines  
â€¢ Inadequate recruitment of participants by [CONTACT_737]  
â€¢ Discontinuation of further deve lopment of the Sponsorâ€™s compound  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  72/84 
  Appendix 3 Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
Definitions  
Adverse Event  
An AE is any untoward medical occurrence in a participant administered a pharmaceutical 
product, regardless of causal relationship with this treatment. Therefore, an AE can be any 
unfavorable  and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of a medicinal product, regardless if it is 
considered related to the medicinal product.  
For surgical or diagnostic procedures, the cond ition/illness leading to such a procedure is 
considered as the AE rather than the procedure itself.  
The Investigator is required to grade the severity or toxicity of each AE.  
Investigators must assess the severity of AEs per the Qualitative Toxicity Scale,  as follows:  
Mild:  The participant is aware of the event or symptom, but the event or symptom 
is easily tolerated.  
Moderate:  The participant experiences sufficient discomfort to interfere with or reduce 
his or her usual level of activity.  
Severe:  Significa nt impairment of functioning: the participant is unable to carry out 
his or her usual activities.  
Investigators must also systematically assess the causal relationship of AEs to study 
intervention (including any other non -study interventions, radiation the rapy, etc.) using the 
following definitions. Decisive factors for the assessment of causal relationship of an AE 
to the investigational medicinal product ( IMP) treatment received in the parent study 
include, but may not be limited to, temporal relationship  between the AE and the IMP 
treatment received  in the parent study , known side effects of the IMP treatment received  
in the parent study , medical history, concomitant medication, course of the underlying 
disease, and the MRI procedure (if applicable) . 
Unre lated:  Not reasonably related to the study intervention. AE could not medically 
(pharmacologically/clinically) be attributed to the study intervention under 
study in this clinical study protocol. A reasonable alternative explanation 
must be available.  
Rela ted: Reasonably related to the study intervention. AE could medically 
(pharmacologically/clinically) be attributed to the study intervention under 
study in this clinical study protocol.  
Abnormal Laboratory Findings and Other Abnormal Investigational Findi ngs 
Abnormal laboratory findings and other abnormal investigational findings (e.g., on an ECG 
trace) should not be reported as AEs unless they are associated with clinical signs and 
symptoms, lead to study intervention discontinuation or are considered oth erwise 
medically important by [CONTACT_737]. A positive test for COVID -19, with or without the 
presence of symptoms, would be considered an AE. If a laboratory abnormality fulfil ls 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  73/84 
  these criteria, the identified medical condition (e.g., anemia  or increa sed alanine  amino 
transferase ) must be reported as the AE rather than the abnormal value itself.  
Serious Adverse Events  
An SAE is any untoward medical occurrence that at any dose:  
â€¢ Results in death  
â€¢ Is life -threatening. Life -threatening refers to an event in  which the participant is at risk 
of death at the time of the event, not an event that hypothetically might have caused 
death if it was more severe  
â€¢ Requires inpatient hospi[INVESTIGATOR_43928]  
â€¢ Results in persistent or signific ant disability or incapacity  
â€¢ Is a congenital anomaly or birth defect  
â€¢ Is otherwise considered to be medically important. Important medical events that may 
not result in death, be life -threatening, or require hospi[INVESTIGATOR_470683], b ased upon appropriate medical judg ment , they may jeopardize the 
participant or may require medical or surgical intervention to prevent one of the 
outcomes listed above. Examples of such events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abuse  
For the purposes of reporting, any suspected transmission of an infectious agent via a study 
intervention is also considered an SAE, as specified below for reporting SAEs  and adverse 
event s of special interest ( AESIs ). 
Events that Do Not Meet the Definition of an SAE  
Elective hospi[INVESTIGATOR_8609]. However, all events leading to 
unplanned hospi[INVESTIGATOR_43931] (i.e., 
undesirable effects of any administered treatment) must be documented and reported as 
SAEs.  
Events Not to Be Considered as AEs/SAEs  
Medical conditions present at the initial study visit that do not worsen in severity or 
frequency during the study are defined as Baseline Medical Conditions and  are not to be 
considered AEs.  
MS Relapses  
In this protocol, symptoms and signs of relapse or worsening of MS will usually be 
captured in the context of the efficacy assessment and  recorded on the relapse module of 
the eCRF. Therefore, symptoms, relapses or worsening of MS will not be considered as 
AEs nor captured on the AE module of the eCRF unle ss considered possibly or probably 
related to the IMP (i.e. worsening is not consistent with the anticipated natural progression 
of the disease).  
 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  74/[ADDRESS_603210] for this study defined in the  Section 6.9 should be considered as medically 
significant AEs. 
Recording and Follow -Up of AE and/or SAE  
It is important that each AE report include a description of the event, its duration (onse t 
and resolution dates and also onset and resolution times, when it is important to assess the 
time of AE onset relative to the recorded study intervention administration time), its 
severity, its causal relationship with the study intervention, any other p otential causal 
factors, any treatment given or other action taken, including dose modification or 
discontinuation of the study intervention, and its outcome. In addition, serious cases should 
be identified,  and the appropriate seriousness criteria documen ted.  
Specific guidance is in the CRF Completion and Monitoring Conventions provided by [CONTACT_429].  
Reporting Serious Adverse Events and  Adverse Events of Special Interest  
Serious Adverse Events  
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (within a maximum of 24 HOURS after becoming aware of the event) inform 
the Sponsor or its designee using the electronic SAE report form in the electronic data 
capture ( EDC ) system.  Any ADRs (assessed as related to cladribine by [CONTACT_470739]/ORACLE/CLARITY -EXT) must 
be recorded in the eCRF as well.  If the ADR information is captured in the subjectâ€™ s 
medical chart already at the time of enrolment then the event is not considered to be of new 
awareness and it is expected to be reported in the Medical History page (e.g. awareness 
date prior to ICF date). If the ADR is reported by [CONTACT_470740] e of enrolment or 
after that then the event is considered of new awareness, and it is expected to be reported 
in the ADR page (e.g. awareness date is after ICF date). Reporting of SAEs using a paper 
report form is required as a back -up method only for an ED C system failure. Names, 
addresses, and telephone and fax numbers will be included on the paper form. All 
information from the paper form must be transcribed into the electronic form as soon as 
the system becomes available.  
In exceptional circumstances, an  SAE (or follow -up information) may be reported by 
[CONTACT_756]; in these cases, an electronic SAE report form must be completed immediately 
thereafter.  
Relevant pages from the CRF may be provided in parallel (e.g., medical history, 
concomitant drugs). Additi onal documents may be provided by [CONTACT_737], if 
available (e.g., laboratory results, hospi[INVESTIGATOR_27450], autopsy report).  
The Investigator must respond to any request for follow -up information (e.g., additional 
information, outcome, final evaluation, other records where needed) or to any question the 
Sponsor/designee may have on the AE within the same timelines as those noted above for 
initial reports. This is necessary to ensure prompt assessment of the event by [CONTACT_470741] : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  75/84 
  or designee and (as applica ble) to allow the Sponsor to meet strict regulatory timelines 
associated with expedited safety reporting obligations.  
Requests for follow -up will usually be made via the study monitor, although in exceptional 
circumstances the drug safety department may co ntact the Investigator directly to obtain 
further information or to discuss the event.  
Adverse Events of Special Interest  
In the event of a non -serious  AESI, the Investigator will notify the Sponsor/designee by 
[CONTACT_470742] . Serious AESIs must be 
reported in an expedited manner as SAEs, as outlined above. Reporting of non -serious 
AESIs using a paper report form is required as a back -up method only for an EDC system 
failure. Names, addresses, and telephone and fax numbers will be included on the paper 
report form. All information from the paper form must be transcribed into the electronic 
form as soon as the system becomes available.  
  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  76/84 
  Appendix 4 Pharmacog enetics  
Use/Analysis of DNA   
â€¢ Genetic variation may impact a participantâ€™s response to therapy, susceptibility to, 
and severity and progression of disease. Variable response to therapy may be due to 
genetic determinants that impact study intervention absorption, di stribution, 
metabolism, and excretion; mechanism of action of the study intervention; disease 
etiology ; and/or molecular subtype of the disease being treated.  
â€¢ DNA samples will be analyzed  for association of genetic variations with clinical 
outcome measures. Additional analyses may be conducted if it is hypothesized that 
this may help further understand the clinical data.  
â€¢ In addition, DNA samples will be used for research related to mechanism of action,  
and related diseases. They may also be used to develop tests or assays, including 
diagnostic tests related to mechanism of action and indication. Pharmacogenetic 
research may consist of the analysis of one or more candidate genes or the analysis 
of genetic markers throughout the genome or analysis of t he entire genome  (as 
appropriate) .  
â€¢ The results of pharmacogenetic analyses will be reported in the Clinical Study 
Report or a separate study summary  within approximately 2 years after the end of 
the study . 
â€¢ Details on processes for collection and shipment of these samples can be found in 
the Q2 Solutions L aboratory  manual  and flow chart . Post-study, t he Sponsor will 
store the DNA samples in a secure storage space with adequate measures to protect 
confidentiality.  
â€¢ Retention time and possible analysis of DNA sample after the study ends are 
specified in the respective ICF.  
 
  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  77/84 
  Appendix 5 Expanded Disability Status Scale (E DSS) 
 
General  
â€¢ The Evaluating Physician will complete the Expanded Disability Status Scale ( EDSS ).  
â€¢ The same individual should remain as the Evaluating Physician for each patient, except 
when exceptional circumstances make this impossible.  
â€¢ Prior to each neurological assessment, the Evaluating Physician should not refer to any 
previous neurological asses sments carried out on that patient.  
â€¢ The current EDSS will be recorded (i.e. the EDSS as assessed during the visit).  
EDSS SCORING  
â€¢ 0.0 Normal neurological exam [all grade 0 in all Functional System (FS) scores*]  
â€¢ 1.0 No disability, minimal signs in one FS * (i.e., grade 1)  
â€¢ 1.5 No disability, minimal signs in more than one FS* (more than 1 FS grade 1)  
â€¢ 2.0 Minimal disability in one FS (one FS grade 2, others 0 or 1)  
â€¢ 2.5 Minimal disability in 2 FS (2 FS grade 2, others 0 or 1)  
â€¢ 3.0 Moderate disability in one FS (one FS grade 3, others 0 or 1) or mild disability in 3 or 
4 FS (3 or 4 FS grade 2, others 0 or 1) though fully ambulatory  
â€¢ 3.5 Fully ambulatory but with moderate disability in one FS (one grade 3) and one or 2 FS 
grade 2; or 2 FS grade 3 (others 0 or 1) or 5 grade 2 (others 0 or 1)  
â€¢ 4.0 Fully ambulatory without aid, self -sufficient, up and about some 12 hours a day despi[INVESTIGATOR_470684] 4 (others 0 or 1), or combination of 
lesser grade s exceeding limits of previous steps; able to walk without aid or rest some 500 
meters  
â€¢ 4.[ADDRESS_603211] some limitation of full activity or require minimal assistan ce; 
characterized  by [CONTACT_298196] 4 (others 0 
or 1) or combinations of lesser grades exceeding limits of previous steps; able to walk 
without aid or rest some 300 meters  
â€¢ 5.[ADDRESS_603212]  for about 200 meters; disability severe enough to impair 
full daily activities (e.g., to work a full day without special provisions); (Usual FS 
equivalents are one grade 5 alone, others 0 or 1; or combinations of lesser grades usually 
exceeding specificat ions for step 4.0)  
â€¢ 5.5 Ambulatory without aid for about 100 meters; disability severe enough to preclude full 
daily activities; (Usual FS equivalents are one grade 5 alone, others 0 or 1; or combination 
of lesser grades usually exceeding those for step 4. 0)  
â€¢ 6.0 Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk 
about 100 meters with or without resting; (Usual FS equivalents are combinations with 
more than 2 FS grade 3+)  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  78/84 
  â€¢ 6.5 Constant bilateral assistance (canes, crutches,  braces) required to walk about 20 meters 
without resting; (Usual FS equivalents are combinations with more than 2 FS grade 3+)  
â€¢ 7.0 Unable to walk beyond approximately 5 meters even with aid, essentially restricted to 
wheelchair; wheels self in standard wheelchair and transfers alone; up and about in 
wheelchair some 12 hours a day; (Usual FS equivalents are combinations with more than 
one FS grade 4+; very rarely pyramidal grade 5 alone)  
â€¢ 7.5 Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; 
wheels self but cannot carry on in standard wheelchair a full day; May require motorized 
wheelchair; (Usual  FS equivalents are combinations with more than one FS grade 4+)  
â€¢ 8.0 Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of 
bed itself much of the day; retains many self -care functions; generally has effective use of 
arms;  (Usual FS equivalents are combinations, generally grade 4+ in several systems)  
â€¢ 8.5 Essentially restricted to bed much of day; has some effective use of arms(s); retains 
some self -care functions; (Usual FS equivalents are combinations, generally 4+ in sev eral 
systems)  
â€¢ 9.0 Helpless bed patient; can communicate and eat; (Usual FS equivalents are 
combinations, mostly grade 4+)  
â€¢ 9.5 Totally helpless bed patient; unable to communicate effectively or eat/swallow; (Usual 
FS equivalents are combinations, mostly g rade 4+)  
â€¢ 10.0 Death due to MS  
*Excludes cerebral function grade 1  
Note 1: EDSS steps 1.0 to 4.5 refer to patients who are fully ambulatory and the precise step 
number is defined by [CONTACT_470743](s). EDSS steps 5.0 to 9.5 are defined by [CONTACT_470744].  
Note 2: EDSS should not change by 1.[ADDRESS_603213] one FS.  
 
Scores of 4.5 and above are determined by [CONTACT_470745] a s follows:  
4.[ADDRESS_603214] 20 meters; or unilateral 
assistance needed but able to walk between 5 -99 meters  
7.0 Only able to walk between 1 - 5 meters even with assistance  
7.5 Unable to walk more than a few steps (i.e., not able to walk at all or able to walk a 
maximum of about 1 meter)  
8.0-9.5 Investigator judg ment   
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  79/84 
  The guiding principle: if a patient fails to mee t the criteria of a given level, they are 
automatically assigned to the next higher level. If a patient does not need aids to walk (i.e., 
walks unassisted) but can only walk 50 meters, they are to be considered EDSS 6.0 since they 
do not satisfy the criter ia for EDSS 5.5.  
 
  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  80/84 
  Appendix 6 2017 Mc Donald Criteria  (From Thompson, 2018)  
Table: The 2017 McDonald criteria for diagnosis of multiple sclerosis in patients with 
an attack at onset  
 
 Number of lesions with 
objective clinical evidence  Additional data needed for a 
diagnosis of multiple sclerosis  
â‰¥2 cli nical attacks  â‰¥2 None*  
â‰¥2 clinical attacks  1 (as well as clear -cut historical 
evidence of a previous attack 
involving a lesion in a distinct 
anatomical locationâ€ )  None*  
â‰¥2 clinical attacks  1 Dissemination in space  
demonstrated by [CONTACT_470746] a 
different CNS site or by [CONTACT_9268]â€¡  
1 clinical attack  â‰¥2 Dissemination in time 
demonstrated by [CONTACT_470747]Â§ OR 
demonstration of CSF -specific 
oligoclonal bandsÂ¶  
1 clinical attack  1 Dissemination in space  
demonstrated by [CONTACT_470746] a 
different CNS site or by [CONTACT_9268]â€¡  
AND  
Dissemination in time 
demonstrated by [CONTACT_470747]Â§ OR 
demonstration of CSF -specific 
oligoclonal bandsÂ¶  
  
If the 2017 McDonald Criteria are fulfilled and there is no better explanation for the clinical 
presentation, the diagnosis is multiple sclerosis. If multiple sclerosis is suspected by [CONTACT_57216] a 
clinically isolated syndrome but the 2017 McDonald Criteria  are not completely met, the diagnosis is 
possible multiple sclerosis. If another diagnosis arises during the evaluation that better explains the 
clinical presentation, the diagnosis is not multiple sclerosis. An attack is defined in panel 1. *No 
additiona l tests are required to demonstrate dissemination in space and time. However, unless MRI is 
not possible, brain MRI should be obtained in all patients in whom the diagnosis of multiple sclerosis 
is being considered. In addition, spi[INVESTIGATOR_470685] ( CSF) examination should be 
considered in patients with insufficient clinical and MRI evidence supporting multiple sclerosis, with 
a presentation other than a typi[INVESTIGATOR_470686], or with atypi[INVESTIGATOR_117616]. If imaging 
or other tests ( e.g., CSF) are undertaken and are negative, caution needs to be taken before making a 
diagnosis of multiple sclerosis, and alternative diagnoses should be considered. â€ Clinical diagnosis 
based on objective clinical findings for [ADDRESS_603215] attack, in the absence of documented objective neurological findings, can include historical 
events with symptoms and evolution characteristic for a previous inflammatory demyelinating at tack; 
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  81/[ADDRESS_603216] be supported by [CONTACT_23810]. In the absence of residual 
objective evidence, caution is needed. â€¡The MRI criteria for dissemination in space are described in 
panel 5. Â§The MRI criteria for dissemination in tim e are described in panel 5.  
Â¶The presence of CSF -specific oligoclonal bands does not demonstrate dissemination in time per se 
but can substitute for the requirement for demonstration of this measure.  
Panel 3: Considerations to help avoid misdiagnosis of mu ltiple sclerosis  
â€¢ Recognize  that the McDonald criteria were not developed to differentiate multiple sclerosis 
from other conditions but to identify multiple sclerosis or a high likelihood of the disease 
in patients with a typi[INVESTIGATOR_470687] e once other diagnoses have been 
deemed unlikely.  
â€¢ Integration of the history, examination, imaging, and laboratory evidence by a clinician 
with multiple sclerosis -related expertise remains fundamental in making a reliable 
diagnosis of multiple sclerosis or  an alternative diagnosis. In addition to confirming 
dissemination in space and time, diagnostic rigor  in the interpretation of clinical data, 
imaging findings, and test results is necessary.  
â€¢ In the absence of a clear -cut typi[INVESTIGATOR_470688] (panel 1), caution should 
be exercised in making the diagnosis of multiple sclerosis, and the diagnosis should be 
confirmed by [CONTACT_470748] -up. In such cases, the clinician should 
consider postponing making a definitive diagn osis and initiation of long -term disease -
modifying therapi[INVESTIGATOR_014], pending longer follow -up to accumulate additional evidence 
supporting the diagnosis.  
â€¢ Caution should be taken in accepting a historical event as an attack in the absence of 
contemporaneous or cur rent objective evidence providing corroboration.  
â€¢ The threshold for additional testing should be low, including for spi[INVESTIGATOR_470689]: when clinical and brain MRI evidence supporting 
a diagnosis of multiple scler osis is insufficient, particularly if initiation of long -term 
disease -modifying therapi[INVESTIGATOR_470690]; when there is a presentation other than 
a typi[INVESTIGATOR_470686], including patients with a progressive course at onset 
(primary p rogressive multiple sclerosis); when there are clinical, imaging, or laboratory 
features atypi[INVESTIGATOR_470691]; and in populations in which multiple sclerosis is less 
common ( e.g., children, older individuals, or non -white populations).  
Panel 4: 2 017 revisions to the McDonald diagnostic criteria for multiple sclerosis  
â€¢ In a patient with a typi[INVESTIGATOR_470692] , 
demonstration of CSF -specific oligoclonal bands in the absence of other CSF findings 
atypi[INVESTIGATOR_470693] a diagnosis of this disease to be made. This 
recommendation is an addition to the 2010 McDonald criteria.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  82/84 
  â€¢ Symptomatic and asymptoma tic MRI lesions can be considered in the determination of 
dissemination in space or time. MRI lesions in the optic nerve in a patient presenting with 
optic neuritis remain an exception and, owing to insufficient evidence, cannot be used in 
fulfilling the M cDonald criteria. In the [ADDRESS_603217] syndrome could not be included as MRI 
evidence of dissemination in space or time.  
â€¢ Cortical and juxtacortical lesions can be used i n fulfilling MRI criteria for dissemination 
in space. Cortical lesions could not be used in fulfilling MRI criteria for dissemination in 
space in the 2010 McDonald criteria.  
â€¢ The diagnostic criteria for primary progressive multiple sclerosis in the 2017 McD onald 
criteria remain the same as those outlined in the 2010 McDonald criteria, aside from 
removal of the distinction between symptomatic and asymptomatic MRI lesions and that 
cortical lesions can be used.  
â€¢ At the time of diagnosis, a provisional disease co urse should be specified (relapsing -
remitting, primary progressive, or secondary progressive) and whether the course is active 
or not, and progressive or not based on the previous yearâ€™s history. The phenotype should 
be periodically re -evaluated based on a ccumulated information. This recommendation is 
an addition to the 2010 McDonald criteria.  
Panel 5: 2017 McDonald criteria for demonstration of dissemination in space and time 
by [CONTACT_325654] a patient with a clinically isolated syndrome  
â€¢ Dissemination in space ca n be demonstrated by [CONTACT_110882] T2 -hyperintense lesions* that 
are characteristic of multiple sclerosis in 2 or more of 4 areas of the central nervous system 
(CNS ): periventricular,â€  cortical or juxtacortical, and infratentorial brain regions, and the 
spi[INVESTIGATOR_1831]  
â€¢ Dissemination in time  can be demonstrated by [CONTACT_470749] -
enhancing and non -enhancing lesions* at any time or by a new T2 -hyperintense or 
gadolinium -enhancing lesion on follow -up MRI, with reference to a baseline scan, 
irrespective of the timing of the baseline MRI  
*Unlike the 2010 McDonald criteria, no distinction between symptomatic and asymptomatic MRI lesions is 
required. â€ For some patients â€”e.g., individuals older than 50 years or those with vascular risk factors â€”it might 
be prudent for the clinician to seek a higher number of periventricular lesions.  
Substance code : N/A  CLASSIC -MS 
MS700568_0026  
 C O N F I D E N T I A L  
I N F O R M A T I O N  84/84 
  Appendix  8 Principal Investigator [INVESTIGATOR_470694]:  Evaluating the Long -Term Outcome s and Durability of 
Effect Following Tr eatment with Cladribine Tablets for 
Multiple Sclerosis: An Exploratory Phase IV 
Ambispective Study of Patients Who Previously 
Participated in the CLARITY/CLARITY -EXT and 
ORACLE Trials  
Regulatory Agency Identifying 
Numbers:  EudraCT number: 2019 -000069 -19 
Clinical Study Protocol 
Version:  03 July 2020 /Version 2 
Site Number:   
I am responsible for the conduct of the study at this site, and understand and will conduct it 
per the clinical study protocol, any approved protocol amendments, International Council for 
Harmonisation Good Clinical Practice (Topic E6) and all applicable H ealth Authority 
requirements and national laws.  
 
____________________________________  ____________________________  
Signature   [CONTACT_391529], academic degree:  [Insert Name [CONTACT_470754] a single center  study, 
insert from Title Page]  
Function/Title:   
Institution:  [Insert Name [CONTACT_470755] a single center study, insert 
from Title Page]  
Address:  [Insert Full Mailing Address (e.g., Street, City, postal code, 
and Country )] 
Telephone number:  [Insert Full number, including country code]  
Fax number:  [Insert Full number, including country code or â€œNot 
Applicableâ€]  
E-mail address:   
 
  